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Abstract 
 
Schistosomiasis is a chronic parasitic disease and considered by the World Health Organization 
(WHO) to be second to malaria as the most devastating parasitic disease in terms of socioeconomic 
importance and public health impact. Characterisation of the cellular immune response to 
schistosomiasis is well established for Schistosoma mansoni but a comprehensive description of T 
cell-mediated immune responses against S. japonicum infection is lacking. Similarly, study on the 
effect of a particular vaccine candidate on the immune response is important as it can provide 
insight as to how to modulate the immune response in order to develop a more efficacious vaccine. 
Therefore, the aims of this project were to evaluate the T cell immune response to S. japonicum 
infection and following vaccination. 
 
CBA mice were percutaneously exposed to cercariae of S. japonicum and the immune response at 
different time points was determined. There was a relatively robust Th1 immune response to 
schistosomal adult worm antigen preparation (SWAP) at the early phase of infection. However, a 
Th2 immune response was dominant at weeks 6 post-infection, a time point when the highest IgG 
response, determined by ELISA, against both SWAP and, especially, SEA was generated. The 
regulatory immune response was most pronounced at the early phase of the immune response 
followed by a rapid decline at week 6-post infection. 
 
Our laboratory at QIMR Berghofer has targeted the ligand binding domain (LD1) of the insulin 
receptor (SjIR) and triose-phosphate isomerase (rSjTPI) as putative vaccine candidates against 
schistosomiasis japonica, both having generated encouraging levels of protection in mice. 
Consequently an antigen mix comprising the two vaccine proteins (rSjTPI-LD1) was prepared, and 
the immune response generated to it analysed in CBA mice randomly grouped into two groups. The 
first group was subcutaneously injected with rSjTPI-LD1 vaccine formulated with Montanide ISA 
720VG (day 0) and boosted twice (on day 15 and day 30). The second group of control mice were 
injected with PBS and Montanide ISA 720 VG using the same immunization protocol. Two weeks 
after the final booster vaccination, the two groups of mice were challenged with 34 S. japonicum 
cercariae and the immune response at different time points was determined using IgG-ELISA and 
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flow cytometry. There were partial but significant reductions in worm and liver egg burdens in the 
vaccinated animals compared with the adjuvant control group indicating the vaccine had generated 
partial protection in the mice. In addition, significantly higher levels of anti-rSjTPI and anti-rSjLD1 
IgG antibodies were induced in the vaccinated group with the peak level occurring at week 4 post-
challenge. Moreover, rSjTPI-LD1 induced both Th1 and Th2 immune responses at the early phase 
of the immune response mediated by CD8
+
 and γδ T cells; a Th17-mediated response induced at a 
later stage. rSjTPI-LD1 significantly induced a regulatory T cell (Treg) immune response in 
vaccinated mice.  
 
Overall, depletion of Tregs may improve the efficacy of rSjTP-ILD1 and further study on γδ T cells 
with regard to vaccine-induced immunity against schistosomiasis may pave the way to the 
development of a more efficacious vaccine. 
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1.3.Background 
 
Schistosomiasis, also called bilharzia, bilharziasis, or snail fever, is a chronic parasitic disease 
caused by blood flukes (trematodes) of the genus Schistosoma. It was first discovered by the 
German surgeon Theodor Bilharz, who identified the etiological agent Schistosoma haematobium in 
1851, when working in Cairo. Human infection is caused by five main species, namely Schistosoma 
mansoni, S. japonicum, S. mekongi, S. intercalatum and  S. haematobium; the latter causes 
urogenital disease [1] and the others are responsible for intestinal and hepatic schistosomiasis  [2, 
3].  Schistosomiasis is endemic in 74 countries. More than 200 million people are infected 
worldwide of whom 20 million are symptomatic and 20 million have severe disease, with a further 
700 million people at risk of infection [4, 5]. S. mansoni occurs in Africa, South America, the 
Arabian Peninsula, the Mediterranean and the Caribbean. Schistosomiasis caused by S. 
japonicum (the Oriental or Asiatic form), is confined to the People’s Republic of China, The 
Philippines and small pockets of Indonesia. S. haematobium is endemic in Africa and the eastern 
Mediterranean and it is a major risk factor for urinary bladder cancer [6],  whereas  S. intercalatum 
and S. mekongi are restricted to central Africa and the Mekong  River basin, respectively [4, 7]. 
Currently, the World Health Organization (WHO) considers schistosomiasis to be second only to 
malaria as the most devastating parasitic disease  in terms of socioeconomic importance and public 
health impact [8]. The disease is associated with many conditions such as anaemia, malnutrition, 
chronic pain, exercise intolerance, developmental defects and poor school performance [9, 10]. 
Furthermore, schistosomiasis impacts on the aetiology and transmission of human 
immunodeficiency virus (HIV/AIDS) [11, 12], tuberculosis  [12, 13] and malaria [14, 15],  and vice 
versa. 
 
1.4. Biology, life cycle features and transmission 
 
The schistosome life cycle is shown in Figure 1. Schistosomes, unlike other trematodes, are 
dioecious, with separate male and female worms. However, they form pairs so that the female 
reproductive maturation is efficient and several studies undertaken in vitro shown the rate of 
oviposition and maturation of eggs are significantly lower among unpaired female worms than 
those that are paired with male worms [16]. Adult schistosomes are cylindrical in shape (7-20 mm 
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in length), are white or greyish in colour, have a surface tegument, two terminal suckers, a blind 
digestive tract and reproductive organs. The surface tegument has a very dynamic feature of 
changing itself regularly and it has a unique structure of two lipid bi layers, a plasma membrane and 
host proximal membranocalyx. This enables the schistosome worm to evade the immune system 
and also obtain critical nutrients [17]. The male adult worm has a groove (the gynaecophoric canal) 
within which the longer and thinner female worm resides and the worm pair lives within the 
perivesical (S. haematobium) or mesenteric (the other species) venous plexus. Schistosomes feed on 
blood and the female produces hundreds (S. mansoni and S. haematobium) to thousands (S. 
japonicum) of eggs daily which are released within the vasculature; they cross the endothelium and 
basement membrane of the vein, and travel through the intervening tissue, basement membrane and 
epithelium of the intestine (S. mansoni and S. japonicum) or bladder (S. haematobium) into the 
exterior. A larva (the miracidium) develops within six days inside the egg and releases proteolytic 
enzymes and other proteins  through ultramicroscopic pores of the egg shell which enable the egg  
to move from the venules to the lumen of the bladder or intestine and eventually to the outside 
environment in urine or faeces: however, more than 50% of the eggs are trapped within tissues in 
the body (mostly liver and intestine) where they induce a granulomatous host immune response and 
eventually die [4, 18].  
 
A schistosome egg that is shed into the external environment needs fresh water to hatch the free 
living, ciliated miracidium which then infects an appropriate snail vector; Biomphalaria in the case 
of S. mansoni, Oncomelania for S. japonicum and Bulinus for S. haematobium. Within the snail, the 
miracidium undergoes a process of asexual reproduction, giving rise to mother and then daughter 
sporocysts within which are produced cercariae with embryonic suckers and characteristic 
bifurcated tails, which are shed periodically from the snail into the water. The asexual reproductive 
phase inside the snail requires 4-6 weeks before infectious cercariae are produced. An individual 
snail, infected with a single miracidium, can shed thousands of cercariae every day for several 
months. On finding a suitable mammalian host, cercariae (which can remain infectious for 1-3 days) 
penetrate the human skin (in case of S. japonicum they also infect other mammalian hosts such as 
pigs, sheep, goats and buffaloes)  to become schistosomula, they enter the vasculature and migrate 
via the lungs to the portal system where they mature into adult worms in 5-7 weeks [4, 19, 20]. 
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Figure 1. 1. Life cycle of human schistosomes (Adapted from Ross AGP, Bartley PB, Sleigh AC, 
Olds GR, Li Y, Williams GM, McManus DP: Schistosomiasis. N Eng J Med, 346:1212-1220. 
Copyright © (2002) Massachusetts Medical Society.  Reprinted with permission. Note: unlike the 
African schistosomes, S. japonicum utilizes a range of mammalian species, notably bovines, as 
reservoir hosts. (Adapted from reference [197]) 
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The spread of schistosomiasis can be accelerated by different factors related to host population 
migration and expansion and the development of new water resources. As examples, displaced 
refugee populations introduced intestinal schistosomiasis  into Djibouti and Somalia [21], whereas 
construction of the Diama Dam that was built on the Senegal River in the 1980s resulted in the 
emergence of S. mansoni in Senegal and Mauritania [21]. Schistosomiasis emergences or re-
emergences have resulted from other large-scale hydro-projects such as the Aswan Dam in Egypt, 
the Gezira-Managil Dam in Sudan, the Melkasadi Dam in Ethiopia, and the Danling, Huangshi and 
Three Gorges Dams in China [4, 22].  
 
1.5. Why a vaccine for schistosomiasis?  
 
Human treatment with praziquantel (PZQ) is playing a central role in the control and prevention of 
schistosomiasis, being the only effective drug currently available [23]. The drug has important 
features including good efficacy, safety, operational convenience and low cost. However, the drug 
does not prevent re-infection and its exclusive use for the prevention and control of schistosomiasis 
is problematic; having been used for more than three decades,   the emergence of PZQ-resistant 
schistosomes is a continual threat. Indeed, a number of reports have appeared on the emergence of 
reduced susceptibility to PZQ in the African schistosomes [24-29] but as yet not for S. japonicum 
[30, 31]. The other drawbacks of PZQ are its poor activity against immature schistosomes, resulting 
in sub-optimal outcomes during mass drug administration campaigns and, as its mechanism of 
action remains unclear, the design of  alternative drug formulations has proven difficult [23]. 
Further, the continued administration of the drug in isolated endemic areas is challenging because 
of the high demand for substantial infrastructure to ensure its effective delivery.  
 
Until the introduction of PZQ in the 1970’s, snail control through the use of molluscicides, such as 
niclosamide, was utilized as the major intervention for the prevention of schistosomiasis [32]. 
However, poor regulation of the molluscicide dose may seriously affect the environment, being 
toxic to fish, so that local communities may not accept it as a control option [33]. Moreover, 
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molluscicides are effective for only a short duration, so that a small number of snails may survive 
treatment and these would be sufficient for the transmission cycle to continue. Currently, unless 
there is a special demand or circumstance, mollusciciding in isolation is not the recommended 
method for the prevention and control of schistosomiasis [23]. 
 
In order to prevent, control and finally eliminate schistosomiasis, vaccination will likely be required 
as a key component of an integrated approach comprising as well, mass chemotherapy, targeted 
mollusciciding, environmental modification, health education and improved sanitation. Besides 
human vaccination, in the case of the African schistosomes, bovines represent important targets for 
vaccination against schistosomiasis japonica taking into consideration its zoonotic nature [34]. 
Indeed, it has been clearly established that  bovines are  major reservoir hosts in China, contributing 
up to 90% of  the S. japonicum egg contamination [35]. Similarly, very high prevalence (up to 90%) 
of schistosomiais japonica has been reported recently in bovines in Samar province in the 
Philippines [36-38]. Additionally, bovines produce much more faeces on a daily basis than do 
humans. Previous mathematical modelling has revealed that an anti-fecundity schistosomiasis 
vaccine for bovines with a 75% efficacy and 75% coverage can reduce the reproduction rate 
sufficiently to achieve long term elimination [39]. Therefore, a transmission blocking vaccine for 
use in bovines could serve as a vital component in the control of S. japonicum [40], whereas at the 
same time vaccines against S, mansoni and S. haematobium, for clinical application in humans, 
should also be developed. These latter human vaccines would likely be administered to children 
who comprise the most affected age groups because they have frequent water contact with 
infectious schistosome cercariae. Importantly, the fact that in schistosome-endemic communities 
there is likely to be continuous exposure to these larvae, would negate the requirement for a booster 
dose of vaccine [7]. However, no commercial vaccines are currently available against 
schistosomiasis, thereby emphasising the need to continue efforts aimed at their future 
development.  
 
This overview considers the protective immune response generated against schistosomiasis in order 
to provide insight into effective vaccine design and also critically evaluates the current status of 
vaccine development for the African and Asian schistosomes. 
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1.6. The immune response against schistosomiasis 
1.6.1. General considerations 
A mammalian host with schistosomiasis is confronted by different schistosome life cycle stages: the 
penetrating cercariae, migrating schistosomula, adult worms and eggs, all expressing many different 
antigens which interact with the host immune system. To understand the immune response to 
schistosomiasis in detail, murine experimental infection models have been commonly used, with S. 
mansoni, being the most studied [41]. Due, in part, to the problems in maintaining the intermediate 
snail hosts (Oncomelania spp.), relatively fewer laboratory studies  have focused on  S. japonicum 
[41], whereas it has proven difficult to investigate S. haematobium as it cannot effectively mature, 
migrate and infect the venous plexus and deposit eggs in the bladders of mice. Fortunately, 
however, the recent development of microinjection of purified viable S. haematobium eggs directly 
into the bladder wall has begun to provide a clearer picture of the pathogenesis this schistosome 
species induces [42]. 
 
During cercarial penetration of the mammalian host, there is the induction of polymorphonuclear 
and mononuclear immune responses coordinated by the production of pro-inflammatory cytokines 
including IL-1β, IL-12, TNFα, MIP1α and IL-6 and by mediators (IL-10 and prostaglandins) that 
regulate the immune response and eosinophilia are observed. This innate immune inflammatory 
response occurs in the skin within hours of cercarial invasion [43, 44]. 
 
Studies using irradiated larvae of schistosomes showed that their migration to the lung (Figure 1) 
ended up with their death due to a protective immune response. These lung stage schistosomula 
were the main target of the immune response and Th1 polarized immunity (IFN-γ producing T 
cells) is prominent in the spleen at this time [45]. However, in a natural infection, due to the fact 
that the parasite evades the immune response, it can survive for many years in the host [41]. 
 
 The immune response is the cause of the chronic morbidity associated with schistosomiasis and it 
is the T-cell dependent  immune responses of the host,  in particular, which are targeted towards the 
eggs trapped in liver and intestinal tissues ( S. mansoni and  S. japonicum) and the bladder (S. 
haematobium). The trapped eggs secrete many antigens and other components which trigger a 
granulomatous-type inflammation, and the resulting granuloma that are formed contain collagen 
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and can cause severe hepatic periportal (Symmer’s) fibrosis  in the case of intestinal schistosomiasis 
[46]. 
 
1.6.2. The immune response against schistosomiasis in animals 
 
Animal models have played an important role in unravelling the immune response generated against 
schistosomiasis. In particular, mice have been used in studies investigating the basic immunology 
and the mechanisms of pathogenesis and in the testing of vaccine candidates, although a number of 
basic differences are evident between murine and human  schistosomiasis [47]. Furthermore, it has 
been recently speculated that schistosome vaccine trials in mice may be inherently flawed, resulting 
in the generation of inaccurate protective efficacy data [48]. 
 
In general, the immune response to schistosomiasis in mice occurs in different phases sequentially. 
In the first five weeks of infection, mice display a T helper 1 (Th1) response which is  followed by a 
T helper 2 (Th2) cytokine dominated response, coinciding with the commencement of eggs being 
released from adult female worms [49]. The Th1 response is characterised by an increase in 
proinflammatory cytokines such as interleukin IL-1, IL-12, TNF-α, and interferon IFN-γ targeting 
schistosomula and immature adult worms [19]. Classically activated macrophages (CAM ф), also 
called M1 macrophages, are induced by  IL-1, IL-12, TNFα and IFN-γ  through the induction of the 
expression of inducible nitric oxide synthase (iNOS), which ultimately generates nitric oxide (NO) 
by acting on the amino acid L-Arginine [50]. The immune response in humans causes, in the first 
instance, an acute form of schistosomiasis characterized by febrile illness (Katayama fever) that 
peaks 6-8 weeks post infection and usually manifests before the appearance of the eggs in the stool; 
surprisingly, many individuals who live in schistosomiasis endemic areas are asymptomatic [51]. A 
study conducted in C57BL/6 Il4
-/-
 mice, which were infected with S. mansoni, showed that a 
proinflammatory response, caused by acute schistosomiasis, is lethal if the mouse is unable to 
mount a Th2 immune response to regulate the initial inflammatory response [19]. 
 
Until recently, it was considered that the Th1 response during schistosomiasis is directly followed 
by a Th2 response. However, there is now evidence describing other unique CD4
+
 T cell 
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subpopulations called Multiple Cytokine Producing Hepatic T cells (MCPHT cells). These cells are 
found in the murine liver and they secrete unconventional cytokine profiles during the time between 
the Th1 and Th2 mediated immune responses, termed the transition phase. These cells secrete IL-4, 
IL-13 and IFN-γ simultaneously. Furthermore, IL-18 plays a role in expansion of these cells in the 
host liver but the factors determining the generation of the MCPHT cells remain unknown [52]. 
 
 
After the deposition of schistosome eggs, at about 6 to 8 weeks post infection, the immune response 
in mice switches to a pronounced Th2 response in which  high levels of  IL-4, IL-5, IL-10, IL-13 
and immunoglobulin E (IgE ) are produced [19, 51]. The deposited eggs trigger the Th2 immune 
response when exposed to dendritic cells (DCs). DCs are important innate immune cells and have 
the ability to present antigen to T cells, connecting innate immunity with  the adaptive immune 
response [53]. The schistosome egg and its products, such as soluble egg antigen (SEA) and 
purified components such as omega 1, condition DCs to mount a Th2 immune response through 
decreasing the expression of co-stimulatory molecules (CD80 and CD86), reducing the interaction 
with T cells, and impairing the production of IL-12 by the DCs [54]. Basophils are another immune 
cell involved in the Th2 immune response against schistosome eggs and are involved in the 
production of the Th2 cytokines, IL-4 and IL-13[54]. The Th2 immune response eventually results 
in the development of granulomas around the eggs which are composed of eosinophils, CD4
+
 T 
cells and macrophages and collagen fibres are formed which surround  the individual embryos [19]. 
This granuloma formation protects  hepatocytes from toxic chemicals  that can be released from  the 
eggs and this is clearly evident in T cell- depleted mice infected with S. mansoni which develop 
necrosis in the liver and intestinal mucosa [55]. Furthermore, it has been shown, using 
immunocompromised mice, that an intact T cell response plays a role in the process of egg 
excretion from the host although the precise mechanism involved remains unknown [56]. 
 
 
A prolonged Th2 response may be harmful for the host since it can result in fibrosis [57], with IL-
13 being the main component responsible for the development of this pathology [58]. IL-10, 
regulatory T cells (Tregs) and alternatively activated macrophages (AAM), also known as M2 
macrophages, regulate the prolonged Th2 immune response in the chronic disease stage (at 10 
weeks post-infection) [50, 51, 59, 60]. IL -10 induces B cells to class switch from producing IgE to 
IgG4 [61]; IgG4 is known to have an anti-inflammatory function and is a poor stimulator of 
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complement activation because of its low affinity for C1q [62]. Mice, double deficient for IL-4/IL-
10 or IL-12/IL-10, develop a lethal granulomatous inflammation, clearly indicating that IL-10 is 
crucial for regulating the activity of both Th1 and Th2 cells [63]. In addition, the secreted IL-10 
inhibits the production of IL-12, IL-18 and TNF, and suppresses the accessory cell activity of both 
macrophages and DCs [59]. The Tregs function by secreting IL10 and transforming growth factor β 
(TGF-β) [54, 59]. Natural Tregs express high levels of IL-2 receptor (CD25) which has the effect of 
consuming IL-2 so that there will be deprivation of this growth factor (IL-2) in the 
microenvironment whereas T effector cells express low levels of CD25 and thus have insufficient 
access to IL-2 so that eventually their proliferation will be limited [64]. Macrophages can also 
regulate the T effector response. Macrophages are alternatively activated in the presence of IL-4 
and IL-13 and commence expressing arginase, which converts the amino acid arginine to proline. 
By consuming arginine, which is important for CD4
+
 T cell proliferation, macrophages limit the 
extent of the immune response generated [65]. 
 
In addition to the immune cells described above, a recent study has shown that innate lymphoid 
cells, natural killer (NK) cells and natural killer T cells (NKT), in the mesenteric lymph nodes 
(MLN) of C57BL/6 mice are involved in the immune response against S. japonicum [66]. This 
work also indicated that the infection induced the production of MLN NK and NKT cells which 
might play roles in modulating the classical T cell response, and in general, the study concluded that 
these cells changed significantly in regards to different features like content (cell number), 
phenotype and function, which might have contributed to the type and intensity of the immune 
response generated [66]. 
 
 
Until recently, studies on schistosomiasis immunopathology of schistosomiasis suggested only Th1 
and Th2 cells were involved. However, new evidence indicates there is a relationship between 
severe pathology  and IL-17-producing CD4
+
 T helper (Th17) cells [67]. For instance, a large 
amount of IL-17 is produced by hepatic lymphocytes after a C57BL/6 mouse is infected with S. 
japonicum. IL-17 plays a key role in granulomatous inflammation and fibrosis generation in the 
liver [68]. Furthermore, it has been shown that IL-17A, administered to S. japonicum-infected 
C57BL/6 mice, had no effect whereas the administration of anti-IL-17A resulted in a reduction both 
in worm numbers and egg burden [69]. This has potential implications for developing a 
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schistosomiasis vaccine in that modulating Th17 cells or IL-17 during vaccination could improve 
the protective capacity of the vaccine candidate. 
 
 
In addition to T cell-mediated responses, humoral factors play an important contribution in the 
immune response to schistosomiasis. In the mouse model it has been shown that B cell- deficient 
mice singly vaccinated with radiation-attenuated S. mansoni cercariae are significantly less well 
protected against challenge infection than vaccinated wild type C57BL/6 mice, suggesting a role for 
antibodies in immunity [70, 71]. Furthermore, it has been shown that S. mansoni can evoke the 
generation of B cells that regulate the immune response to schistosomiasis [72]. Surprisingly, S. 
mansoni can also reduce surface CD23 expression on B cells by producing a 15 kDa fragment (SG-
sCD23) which prevents IgE from binding to CD23 and to FcεRI, which the parasite uses as a 
mechanism to evade the host’s IgE mediated granulocyte attack [73]. Immune resistance against 
schistosome infection is more pronounced in rats than mice. In rats, only 25-30% of larvae reach the 
liver. This form of resistance is thought to be due to immune complexes formed by IgE and IgG2 
with macrophages, mast cells, complement, eosinophils and platelets combining to eliminate 
schistosomula [74, 75].  
 
 
In contrast to the large body of work on rodent models of schistosomiasis, there is very limited 
information available concerning immunity in natural animal hosts of schistosomiasis such as 
bovines (water buffalo and cattle) which are important reservoirs for S. japonicum and potential 
recipients of a transmission blocking veterinary vaccine, once a suitable candidate becomes 
available. Consequently, increased knowledge of the immune response to schistosomiasis in 
bovines is essential, particularly as the attraction of developing and field testing an animal vaccine 
that prevents schistosome transmission is gaining increasing attraction as a realistic option for 
aiding in the control of zoonotic schistosomiasis [34, 76, 77].  
 
 
Some studies, albeit limited, have shown that effective immune responses are generated against S. 
japonicum in larger domestic animals. For example, a self-cure phenomenon after S. japonicum 
infection has been observed in water buffalo and pigs in China where the worm burden decreased 
sharply following parasite challenge [78]. Furthermore, an age-related resistance was reported 
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among water buffalo, but not cattle, after they were treated with PZQ and reinfection rates assessed 
[79]. In another study, the worm length, worm recovery rate and paired worm percentage were 
significantly higher and there were more egg granulomas among yellow cattle (another susceptible 
host for S. japonicum) than water buffalo [80]. Additionally, more pronounced pathological damage 
and a shift to Th2-type polarized immunity from a Th1 cell response were observed in the infected 
yellow cattle compared with water buffalo where no shift was evident [80]. 
 
 
A recent important study reported on the migrating larvae of S. japonicum after their introduction 
into previously exposed and re-challenged water buffalo [81]. A strong allergic type inflammatory 
response, with increased IL-5 transcription but decreased IL-10 transcription, was observed in the 
skin and a prominent type 2 profile was evident in skin draining lymph nodes in stimulated 
lymphocytes. In contrast, a type 1 profile was observed in the lung draining lymph node, and the 
two immunological profiles appeared consecutively.  Moreover, a strong type 2 immune response 
with leukocyte and eosinophil infiltration, including the formation of granulocytic abscesses, was 
evident at the site of cercarial penetration. This represents a significantly different immune response 
from that recorded in naive and permissive animal models (such as the mouse) and might indicate 
that it is this type of immunity which will be required to protect water buffalo [81]. 
 
 
Overall, these limited but informative studies on water buffalo and cattle provide some 
understanding, on the generation of immunity to schistosomiasis in natural hosts and they provide 
some insight which may underscore the future design of an effective transmission blocking 
veterinary vaccine, even though further detailed studies to explain, for example, the mechanism of 
self-cure in water buffalo are still necessary. 
 
1.6.3. Immune response to human schistosomiasis 
In contrast to the extensive information available on the immune response to schistosomiasis in 
animal models, far fewer studies have been conducted on the mechanisms of protective immunity in 
humans. There are many challenges in studying immunity to schistosomes in humans including 
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ethical issues and the fact that almost every infected individual in an endemic area will harbour  a 
co-infection with another parasite or microbial pathogen [82]. 
 
 
In general, studies conducted to date on the human immune response to schistosomiasis indicate 
that there is development of an age-acquired immune resistance to reinfection following 
chemotherapy of subjects in endemic areas; this feature cannot be explained by differences in 
patterns of water-contact [4]. Some reports have correlated this resistance with the development of a 
Th2-type immune response and the generation of protective IgE antibodies mounted against larval 
antigens and adult worms. IgE can also induce eosinophils to secrete cytokines against 
schistosomula. Further, it has been shown that IgG4 can block the IgE pathway and even can block 
the killing effect of eosinophil-dependent cytotoxicity (mediated by other IgG effector antibodies) 
on  schistosomula [4, 83]; therefore, high levels of  IgG4 have been correlated with susceptibility to 
reinfection [84]. Generally, however, it is impossible to dissociate the effect of either IgE or IgG4 
on reinfection, if the opposite action of both isotypes to each other is not taken into account [85]. 
Moreover, it has been shown that a low IgE: IgG4 ratio is correlated with infection and a recent 
study conducted on S. haematobium indicated that a low IgE: IgG4 ratio is also associated with a 
reduced level of CD4
+
 memory T cells [86]. Furthermore, an increased level of circulating CD23
+
 B 
cells (a B cell subset) has been shown to correlate with resistance to S. mansoni reinfection [87, 88]. 
  
 
 Evidence sheds some additional light on the human protective immune response against 
schistosomiasis. There is a report of individuals in Brazil (“endemic normals” (EN)), who are 
continually faecal-egg negative, they have never received treatment with anthelmintics, they are 
exposed continuously to infection and appear to be naturally resistant; they are characterized by 
being negative based on fecal egg count [89]. The immune response to crude S. mansoni extracts 
observed in these people is different and higher than chronically infected individuals and also 
differs from individuals who are resistant to reinfection after specific chemotherapy [46]. For 
example, the EN group mounted a strong Th2 type immune response with higher levels of IgE 
compared with IgG4 against the schistosomula tegument whereas the opposite pattern was evident 
in the chronically infected group i.e. a high level of IgG4 and a low level of IgE [90].  Also, the EN 
individuals generated a higher level of IFN-γ when compared with other groups [91]. Additionally, 
levels of IgG4 against soluble worm antigen preparation (SWAP), soluble egg antigen (SEA) and 
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Sm 22.6 were lower in EN individuals compared with susceptible subjects [92]. Sera from ENs 
provide a potentially invaluable resource to identify novel schistosome molecules and to discover 
candidate vaccine antigens. 
  
 
As acquired immunity to schistosomiasis in humans is age-dependent, it can take considerable time 
to develop. This slow acquisition may be due to the fact that immunity develops after exposure to 
antigens released from adult worms dying either after treatment or naturally [93]. It has been 
proposed that older subjects have repeated exposure to IgE antigens (e.g. tegumental-allergen-like 
protein (TAL) 3) released upon the death of adult schistosome worms and that this leads to 
increased cross-reactivity with invading larval antigens (e.g. TAL5) (82). Progressive accumulation 
of worm/larvae cross-reactivity provides a possible explanation for the age-acquired protective 
immunity evident in individuals from schistosomiasis-endemic areas. Hence, these subjects slowly 
overcome immune evasion by the schistosome parasites and develop partially protective immunity 
[94]. 
 
Taken together, the currently available information regarding the immune response to 
schistosomiasis in humans indicates that potential resistance to infection does occur over time, 
indicating that anti-schistosome vaccine development is feasible although the identification of 
effective candidates remains a major challenge. 
 
1.7. Strategies for the development of novel vaccines for schistosomiasis 
 
Although complex, the schistosome life cycle, with its various stages each expressing distinct 
antigens, provides the possibility of identifying many alternative molecules for vaccine 
development. The fact that the different stages reside in different host niches (larvae in the skin and 
lungs, adults in the liver and intestine or bladder capillaries) can help in the design of possible 
vaccines to prevent migration of schistosome parasites and their maturation to adult worms. 
Importantly, the inability of schistosomes to replicate in the definitive host makes  partial reduction 
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of the parasite burden sufficient to control the disease, strengthening the possibility of developing 
an effective vaccine as a control intervention [95]. Once such a vaccine is available, it would most 
suitably be administered to children (3–12 years of age) since their contact with infected water is 
higher than other age groups.  
 
As indicated earlier, another advantage of vaccinating children is that there might not be a need for 
booster doses as their frequent contact with cercarial-infested water restimulates the immune 
response (6). Moreover, the zoonotic life cycle associated with schistosomiasis japonica provides 
the opportunity to follow another approach by developing a transmission blocking veterinary 
vaccine as exemplified by an ultraviolet-attenuated cercarial vaccine shown to induce significant 
levels of resistance (up to 89% ) in water buffalo [96, 97]. 
 
When identifying a suitable vaccine candidate, it is prudent to select key schistosome molecules 
that are (a) exposed to the host immune system; and (b) are essential for parasite survival. Such 
components may, for example, function in migration, immune evasion, nutrient uptake or 
attachment.  
 
Adjuvant selection, mode of vaccine formation and delivery are other important considerations in 
vaccine design and deployment as it can have a considerable impact on the protective effectiveness 
of the vaccine. It is well known that, in contrast to attenuated cercarial vaccines, other types, such as 
subunit vaccines, require an appropriate adjuvant to help stimulate the immune system. A number 
of different adjuvants are available such as gels, emulsions, particulates, cytokines, microbial 
products (e.g. CPG, cholera toxin) and proteases. Adjuvants can overcome immune senescence in 
older individuals, prolong the immunological memory of a vaccine, broaden the antibody repertoire 
and they can direct the immune system to a Th1 biased, Th2 biased or mixed Th1/Th2 biased 
response [98]. For example, a Th1 driving adjuvant such as IL-12, administered with irradiated 
cercariae, provided up to 90% protection in murine schistosomiasis [99, 100]. Currently, in order to 
increase the protective efficacy of schistosome vaccines, a strategy of combining existing adjuvants 
with novel ones developed based on emerging immunological targets, is recommended [100]. 
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1.8. Current status of vaccine development for S. mansoni and S. haematobium 
1.8.1. General considerations 
In order to develop a suitable vaccine, a series of parameters need to  be considered which include: 
knowledge of key elements of the protective immune response in humans; identifying  and 
characterizing the best target antigens; determining the efficacy of the vaccine candidate by taking 
into account the reduction of parasite burden and reductions in immunopathology; assessing its 
safety; and ensuring an appropriate level of funding is available for infrastructure and qualified 
manpower to perform clinical trials [101]. Over 100 schistosome vaccine antigens have been 
identified, of which about a quarter have shown some level of protection in the murine model of 
schistosomiasis [7] but, somewhat disappointingly, only three molecules, S. mansoni  fatty acid 
binding protein (Sm14), S. haematobium glutathione S-transferase (Sh28GST), and Sm-TSP-2 have 
entered human clinical trials with Smp80 (calpain) undergoing testing in non-human primates 
[102]. 
 
As indicated earlier, a recent report has suggested that the murine model of schistosomiasis, for pre-
clinically testing vaccine candidates may be intrinsically flawed as a result of the fragility of the 
pulmonary capillaries in mice which can prevent maturation of a large  proportion of schistosome 
cercariae upon challenge; this may lead to the incorrect assumption that vaccine antigen-induced  
acquired protective immunity has been generated [48]. This article will no doubt, stimulate vigorous 
debate and its conclusions will require rigorous testing but, with this caveat, some of the S. mansoni 
and S. haematobium vaccine candidates that have been identified are now highlighted below and in 
Table 1.1. 
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1.8.2. Candidate vaccines 
1.8.2.1. Sm-p80 calpain 
Calpain is a calcium activated neutral cysteine protease that has been immunolocalized to the 
tegument of adult worms [46]. Vaccination with Sm-p80, the large subunit of S. mansoni calpain, in 
combination with resiquimod (R848) as an adjuvant and using a prime-boost approach (priming 
with DNA and boosting with recombinant protein) resulted in 49% worm burden reduction, while 
50% protection was achieved using the recombinant protein as primary and boost vaccine 
(immunized and then boosted by recombinant protein) in mice [103]. With the same approach, but 
using a different adjuvant, oligodeoxynucleotide (ODN) 10104, 70% worm burden reduction and 
75% egg reduction was achieved with Sm-p80 [104]. However, in other novel approach where the 
DNA priming and boosting with protein performed in a single day in mice, significant reduction in 
worm burden (33 to 57 %) and marked decrease in egg retention in tissues (34 to 66%) was 
observed [105]. Moreover, a recent a 58% worm burden reduction in baboons (Papio anubis) using 
resiquimod (R848) and CpG ODN, was reported with the Sm-p80-based vaccine [106]. 
 
Using a different approach, a DNA vaccine incorporating  Sm-p80  conferred 59% worm burden 
reduction and 84% decrease in egg production in mice [107], whereas in baboons the vaccine, with 
or without a vector approved for human use (VR1020), resulted in a 38% and 46% reduction in the 
worm burden and a 32% and 28% decrease in egg production, respectively; moreover, antibodies 
and IFN-γ were shown to play an important role in the protective immunity generated in this non-
human primate model [107, 108]. 
 
Recently, Sm-p80 also demonstrated cross-species prophylactic efficacy in S. japonicum with a 
worm reduction of 46.75% in mice and in S. heamatobium in hamster with a worm reduction of 
26.95% [109, 110]. Promisingly, sixty weeks post-vaccination with recombinant Sm-p80, enduring 
antibody titers were detected in mice and IgG specific for Sm-p80 was detected in baboons 5-8 
years after initial vaccination with the Sm-80 DNA vaccine [111]. It is anticipated that the 
recombinant Sm-p80/GLA-SE vaccine, “SchistoShield”, will move forward to phase I/II human 
clinical trials in 2017 [109, 111]. Furthermore, it has also been shown that Sm-p80 has a therapeutic 
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effect in vaccinated baboons through decreasing the numbers of established worms, reducing the 
retention of eggs in tissues and decreasing the number of eggs excreted in faeces [112]. More recent 
data on recombinant Sm-p80 showed a worm reduction of 33.33% -53.13% and 38%  in mice and  
baboon respectively [113, 114] and also in baboon significant reduction in hepatic egg (67.7%) 
[115] and 93.45% reduction on pathology producing female worms was reported [116]. Moreover, 
vaccine immunogenicity of Sm-p80 was assessed using RNA sequencing  and it is revealed that the 
vaccine candidate induced both cellular and humoral immune response and a predominant Th1,Th2 
and Th17 gene signature was obtained [117]. Other study confirmed that Sm-p80 mediated 
protection is not based on complement [118] rather antibody dependent cell mediated cytotoxicity 
(ADCC) showed a positive role [119]. Nowadays, Sm-p80 is ready for human clinical trials [120]. 
 
1.8.2.2. S. mansoni fatty acid binding protein (Sm14) 
Schistosomes lack an oxygen-dependent pathway for the synthesis of sterols and fatty acids. 
Therefore, they are entirely dependent on the mammalian host to provide these essential lipids. 
Schistosomes use a fatty acid binding cytosolic protein (FABP) to absorb, transport and 
compartmentalize fatty acids from the host and, because of this critical biological function, Sm14 
has long been considered a potential vaccine candidate [121]. One of the characteristics of this 
molecule is that it has been shown to be cross-species protective in that in addition to S. mansoni, it 
also protected against Fasciola hepatica infection. Recombinant Sm14 (rSm14) provided up to 67% 
protection in terms of reduced S. mansoni worm burden in outbred Swiss mice without the use of an 
adjuvant, and encouragingly, no autoimmune response was observed even though its structure is 
identical in basic forms with mammalian host homologues [122]. Development of a dual vaccine 
effective against both S. mansoni and F. hepatica has great appeal in terms of human and animal 
health. The rSm14 vaccine entered and successfully completed a phase 1 clinical trial [123], 
confirming its status as safe and immunogenic  and further immunogenicity and safety phase 2 trials 
of Sm14 (adjuvanted with GLA-SE) are planned for schistosomiasis endemic areas in Brazil and 
Africa [124, 125]. 
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1.8.2.3. S. mansoni  tetraspanin protein 2 (Sm-TSP-2) 
The tetraspanins are a group of proteins that are highly abundant in the schistosome tegument where 
they are found at the outer most membrane of the intra-mammalian stage of the parasite, and hence 
are highly exposed to the host immune system [126]. The major tetraspanin proteins in S. mansoni 
are Sm-TSP-1 and Sm-TSP-2 with the latter conferring  protection in S. mansoni challenge animal 
models and also correlating with  protective immunity in naturally resistant people [127]. Sm-TSP-2 
is currently being developed by the  Sabin Vaccine Institute Product Development Partnership as a 
9 kDa recombinant Sm-TSP-2/Alhydrogel® vaccine in combination with the GLA-AF adjuvant; it 
has undergone toxicology studies [128], it has shown good preclinical results, expression of  the 
antigen can be readily scaled up [129] (http://www.sabin.org/updates/pressreleases/phase-1-clinical-
trial-sm-tsp-2-schistosomiasis-vaccine),and has completed a phase one clinical trial (data as yet 
unavailable) and a phase two clinical trial is currently planned to be done in Uganda [130]. In 
contrast, and rather disappointingly, whereas high levels of IgG1 and IgG2 antibodies were 
generated in mice against the recombinant TSP-2 protein homologue from S. japonicum, no 
consistent protective efficacy was achieved [131]. 
 
1.8.2.4. Glutathione S-transferase (Sh28GST) 
Sh28GST is a 28 kDa enzyme that is expressed in subtegumental tissue; it plays a role in fatty acid 
metabolism and prostaglandin D2 synthesis and which may help the parasite evade the host immune 
system. The enzyme present in S. mansoni (Sm28GST) has been tested extensively as a 
recombinant protein vaccine in various experimental models and has shown partial protection in 
terms of reduced worm burdens, inhibition of female worm fecundity and a reduction in egg 
viability [132]. The S. haematobium homologue, Sh28GST (Bilhvax), has entered human clinical 
trials [123, 133]. Cytokine production triggered by this vaccine candidate was shown to be 
influenced by factors such as host age, schistosome infection status and PZQ treatment history and 
this has provided an indication as to the features which should be considered for determining the 
efficacy of the GST-based vaccine during its testing in targeted endemic communities [133]. 
Bilhvax was scheduled to complete a phase 3 clinical trial in 2012 
(https://clinicaltrials.gov/ct2/show/NCT00870649), evaluating whether the vaccine co-administered 
with PZQ could delay pathology relapse due to S. haematobium infection in children; the results of 
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this phase 3 trial showed that Sh28GST (Bilhvax) was safe and immunogenic but sufficient 
protective efficacy was not achieved [134]. Prior phase 1 and 2 clinical trials showed that the 
Sh28GST vaccine was safe for healthy and infected adults and children [135]. Despite these 
encouraging features, Sh28GST has not progressed to an application for licensure [130]. 
 
1.8.2.5. Tegumental protein Sm29 
Sm29 is present in the tegument of adult worms and schistosomula and in its recombinant form it 
induces high production of IgG1 and IgG3 isotypes among individuals resistant to infection and 
reinfection [136]. There are reports that Sm29 in recombinant form can prevent infection in animals 
previously exposed to S. mansoni. For example, 26–48% protection was observed in BALB/c mice 
that were previously infected with the LE strain of  S. mansoni and treated with PZQ [137]. 
Recently an increased level of protection was obtained through combining Sm29 with Sm14 in the 
presence of poly I:C adjuvant; 40.3%, 68.2%, and 57.9% reductions in adult worm burden, liver egg 
burden and intestinal eggs, respectively, was achieved, along with a reduction in granuloma size 
and count in the livers of immunized mice [138]. Another report showed that by fusing Sm29 and 
Sm14, a 48.4% reduction in adult worm burden in mice was achieved [139]. Similarly, fusing Sm29 
with Sm -TSP-2 resulted in an increased reduction (from 22% to 35%) in the number of worms, a 
higher titre of IgG1 and IgG2 antibodies and increased levels of IFN-γ and TNFα than Sm29 alone 
in challenged mice [140, 141]. In a further advance, recombinant Sm29 was subjected to high 
hydrostatic pressure which dissociated the aggregated protein resulting in a successfully folded, 
soluble, stable and structured molecule produced in high yield, which was protective against S. 
mansoni, thereby paving the way for its industrial production [142]. 
 
1.8.2.6. Antioxidants 
The antioxidants Cu–Zn superoxide dismutase (SOD) and glutathione S peroxidase (GPX) induced 
greater than 40% reduction in worm burden when administered as DNA-based vaccine in S. 
mansoni-challenged mice [143]. Similarly, a recent study showed a protective effect against 
schistosomiasis in baboons [144]. These non-human primates, vaccinated with two different 
formulations of SOD (SmCT-SOD and SmEC-SOD) and one of GPX, with a protocol of priming 
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with naked DNA and boosting with the respective recombinant antioxidant proteins encapsulated in 
polylactic acid (PLA) microspheres, showed a good immune response, a reduction in worm 
numbers to varying degrees and a pronounced anti-pathology effect compared with control [144].  
 
1.8.2.7. Digestive tract proteins 
S. mansoni worms ingest host blood which passes through the oesophagus before arriving at an area 
in the gut where many peptidases catalyse its proteolysis. The processing of the blood and the 
resulting uptake of nutrients are functions essential for the survival of the parasite. Blocking these 
critical processes represents an important strategy for vaccine development and a number of 
digestive tract proteins have being tested as vaccine candidates [145]. One example was the trialling 
of a soluble form of schistosome lysosome-associated membrane glycoprotein (Sm-LAMP), located 
in the gastrodermis, which resulted in a reduction in worm burden (16-25%) and in faecal eggs (52-
60%); moreover, its insoluble form produced up to 38% reduction in liver egg burden [146]. 
Another recent study identified a number of oesophageal secreted proteins, encoded by microexon 
genes (MEGs), that are involved in the initial processing of ingested blood and these, along with 
lysosomal hydrolase, also localised to the oesophagus, may prove to be novel immune targets [147]. 
Other examples of digestive proteins as potential vaccine targets are described in Table 1.1  and 
elsewhere [148]. 
 
1.8.2.8. Dynein light chain proteins (DLC/LC8)  
The dynein light chain family (DLC/LC8) domain, which is evolutionarily conserved in different 
organisms, was recently shown to play a protective role against schistosomiasis as some of the 
homologues are present in the distal cytoplasm of cells, in the tegument region and on the 
membrane surface of schistosomes [149]. Recombinant S. mansoni DLC 12 and DLC 13, 
adjuvanted with alhydrogel, demonstrated a 43% and 51% reduction in worm burdens respectively, 
in vaccinated and challenged mice [149]. Furthermore, both DLCs reduced the size of granulomas 
in the hepatic tissue by up to 70%. Their considerable immunogenicity and protective efficacy, 
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coupled  with the absence of any allergic reactivity, encourages their further study as individual 
vaccine antigens or as part of a multicomponent vaccine [149].  
  
1.8.2.9. Attenuated S. mansoni vaccines 
S. mansoni cercariae, attenuated by heat, chemical or ultraviolet treatment, or by ionizing radiation 
(gamma or X-ray), have been shown to provide protection against S. mansoni challenge in several 
mammalian species [46, 150]. Recent studies undertaken with UV-radiation-attenuated cercariae 
given once or, more effectively, multiple times to C57BL/6 mice have confirmed earlier findings 
with significant reductions in  worm and  hepatic and intestinal egg numbers in vaccinated animals 
[151, 152]. Moreover, tegumental changes in the adult worms (swelling, fusion of tegumental folds, 
vesicle formation and loss or shortening of spines on the tubercles) were evident [151, 152]. A 
recent systematic meta-analysis and review of the available publications in the area on mice 
indicated that irradiated cercariae could confer up to 78% protection if used at maximum dosage 
(5000 cercariae) and that, generally, increasing the number of immunizing parasites and decreasing  
the irradiation dose (using the lowest dose of 3krad) and time between the last immunization and 
challenge gave the  maximum level of protection [150]. Although the protection generated waned, 
the analysis showed it remained elevated for at least eight months after vaccination and reinforces 
the view that the level of protection obtained would reduce both schistosome transmission and 
parasite associated morbidity. This emphasises the potential of developing an attenuated cercarial 
vaccine, a concept proposed some years back that might well be worth revisiting [153], with the 
caveat that it would in all likelihood be problematic for human use (perhaps less so for application 
in reservoir hosts of S. japonicum) since such an attenuated vaccine would likely carry too high a 
risk of side effects or of partially or unattenuated parasites reaching the mesenteric veins and 
becoming patent. 
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Table 1. 1. Recent data on S. mansoni vaccine candidates 
 
Antigen Location in 
adult worm 
Identity/Function Immunization 
strategy 
Adjuvant Host Worm 
burden 
reduction 
(%) 
Liver egg 
burden 
reduction 
(%) 
Reference(s) 
Sm-p80 Associated 
with tegument 
inner 
membrane 
Calpain-neutral 
cysteine protease 
Recombinant 
protein 
Resiquimod Mouse 50 16 [103, 104, 
106-108] 
Primed  with 
pcDNA3 and 
boosted with 
recombinant 
protein 
Resiquimod Mouse 49 30 
 
Primed and boosted 
with recombinant 
protein 
Oligodeoxyn
ucleotide 
Mouse 70 75 
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Recombinant 
protein 
Resiquimod Baboon 58 - 
DNA vaccine - Baboon 38-46 32-28 
Fatty acid binding 
protein (FABP) 
(Sm14) 
Whole body, 
Cytosolic 
Absorbs, transports and 
compartmentalizes fatty 
acids from the host 
Recombinant 
protein 
- Mouse 67 - [122] 
Tetraspanin 
protein 2 (Sm-
TSP2) 
Tegument 
apical 
membrane 
Tetraspanin integral 
membrane protein 
Recombinant 
protein 
 Freunds Mouse 57 64 [154, 155] 
Recombinant 
protein 
Alum/CpG Mouse 25 27 
Glutathione S-
transferase 
(Sh28GST) 
Whole body Enzyme involved in 
fatty acid metabolism 
and prostaglandin D2 
synthesis 
Recombinant 
protein 
Aluminium Baboon 0-80 - [156] 
Sm29 Tegument 
apical 
membrane 
Unknown, but has a C-
terminal domain 
DNA vaccine with 
pUMVC3 plasmid 
- Mouse 17-22 - [141, 157] 
Recombinant Complete 
Freunds and 
Mouse 51 - 
                                                                                                                                                                                                                                       25 
                                                                                                                                                                                                                                                     
protein Incomplete 
Freunds 
Sm14+Sm-29 - - Multivalent 
recombinant 
proteins 
Poly (I;C) Mouse 40 68 [138] 
Sm29+Sm-TSP-2 - - Multivalent DNA 
vaccine with 
pUMVC3 plasmid 
- Mouse 24-32 - [140, 141] 
Multivalent 
Recombinant 
proteins 
CpG-Alum Mouse 35 - 
Oesophageal 
gland secretion 
(Sm100.3) 
Oesophagus Digestive tract proteins 
(oesophageal) 
Recombinant 
proteins 
Freunds Mouse 25-32 33 -44 [158] 
Cathepsin 
B1(SmCB1) 
(Combined with  
SG3PDH
a
 +PRX-
Gut 
(gastrodermis) 
Gut protease (cysteine 
peptidase) 
Recombinant 
proteins 
Postulated to 
have inbuilt 
adjuvant 
properties 
Mouse 73 83 [159, 160] 
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MAP
b
)
 
S. mansoni 
Cathepsin B (Sm-
CB) 
 
Gut 
(gastrodermis) 
Gut protease (cysteine 
peptidase) 
Recombinant 
proteins 
CpG 
oligodeoxynu
cleotides 
Mouse 59 56 
Montanide 
ISA 750 VG 
Mouse 60 62 
Schistosome 
cysteine 
proteinase, 
asparaginyl 
endopeptidase 
(SmAE)(Sm32) 
Gut Gut protease  
(Asparaginyl peptidase) 
DNA vaccine - Mouse No 
significant 
reduction 
37 [161] 
Lysosome-
associated 
membrane 
glycoprotein (Sm-
LAMP) 
Gastrodermis processing of ingested 
blood 
Recombinant 
protein 
alum-CpG Mouse 16–25 - [146] 
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Dynein light chain 
proteins 
Unknown evolutionarily 
conserved among 
different organisms 
Recombinant 
protein 
Alhydrogel Mouse  
 
 [149] 
  -DLC 12  
     -DLC 13 
     43 
51   
S. mansoni 
Syntenin 
(SmSynt) 
Intestinal tract Scaffold supporting 
protein 
Recombinant 
protein 
Complete 
Freunds  and 
incomplete 
Freunds 
Mouse 30-37 - [162] 
Radiation-
attenuated  
cercariae  
 
- 
 
- 
 UV -attenuated  - Mouse 43 73 [151] 
Antioxidants 
-Cu/Zn cytosolic 
superoxide 
dismutase  
-signal peptide-
 
 
- 
 
 
 
- 
 
 
 
DNA vaccine 
 
 
 
- 
 
 
Mouse 
 
 
 
44 -60 
 
 
 
 
- 
[143, 144] 
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containing 
superoxide 
dismutase 
-glutathione 
peroxidase 
enzymes 
 
- 
 
 
- 
- 
 
 
- 
DNA vaccine 
 
 
DNA vaccine 
- 
 
 
- 
 
 
Mouse 
 
 
Mouse 
 
 
Baboon 
22 -45 
 
 
23–55 
 
 
17.1 
a
Glyceraldehyde 3-phosphatedehydrogenase ,   
b
peroxiredoxin 
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1.9. Current status of vaccine development for S. japonicum  
1.9.1. General considerations 
Vaccine deployment against S. haematobium and S. mansoni requires the use of clinical vaccines 
for human application. The zoonotic nature of schistosomiasis japonica allows for a complementary 
approach for S. japonicum involving the use of a transmission blocking vaccine in livestock 
animals, particularly bovines [46]. The vaccine would be used in reservoir hosts of S. japonicum to 
reduce transmission to humans [46]. 
 
As indicated earlier, it is estimated that in China 90% of the environmental egg contamination due 
to S. japonicum is from water buffalo and cattle. Water buffalo are also known to be important 
infection reservoirs in the Philippines [163].  Mathematical modelling has shown that to eliminate 
the transmission of S. japonicum in China, and most likely the Philippines, these reservoirs of 
infection, in addition to humans, should be targeted [164]. Therefore, although controlling zoonotic 
schistosomiasis is challenging, it provides an opportunity to utilize a transmission blocking vaccine 
for veterinary application with the goal of prevention and control of infection and disease in humans 
[165, 166]. 
 
1.9.2. Candidate vaccines  
1.9.2.1 Attenuated S. japonicum vaccines  
Vaccination of  bovines with  gamma irradiated schistosomula resulted in a significant  reduction in 
adult worms and liver eggs compared to control animals [167]. Moreover, vaccination of pigs using 
UV attenuated cercariae, produced variable, although highly promising, levels of protection in 
terms of reduced adult worms and hepatic egg burden in animals receiving a single immunization or 
those vaccinated three times [168]; the protective efficacy was shown to be associated with IFN-γ 
and IgG2 antibody production [169]. A pilot study in miniature pigs using similar methodology (but 
incorporating a lower number of challenging cercariae), resulted in more than 80% worm reduction 
[170]. However, it has been reported that unstable and relatively low protection is induced in 
C57BL/6 mice by attenuated S. japonicum cercariae, likely due to the poor Th1 response generated 
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and less robust antibody response, thereby suggesting this mouse strain might be a sub-optimal 
model for studying the mechanisms of immune protection against this schistosome species [171].   
 
1.9.2.1. Paramyosin (Sj97) 
Paramyosin, is a myofibrillar 97 kDa protein present in the muscle layers and the tegument of 
schistososmes that has long been regarded as a vaccine candidate against S. japonicum and S. 
mansoni infection [46]. An early study showed that mice vaccinated intraperitoneally with purified 
paramyosin (without the use of an adjuvant) stimulated 62-86% resistances against cercarial 
challenge [172]. In addition to preventing infection, a longitudinal treatment-reinfection design 
study in Leyte, the Philippines showed that a Th2 bias in response to Sj97 predicted a longer time to 
human reinfection and lower reinfection intensity after treatment with PZQ [173, 174]. Moreover, it 
was reported in the human Leyte cohort that individuals who produce IgE but not IgG4 in response 
to rSj97 had 77% lower reinfection intensity after 12 months of treatment with PZQ [174, 175]. 
Sj97 is now in early preclinical testing with process development and further proof of concept 
studies taking place in mice and water buffalo [135, 174, 176].  
 
1.9.2.2. Sj26GST 
The glutathione S-transferases (GST) are multifunctional enzymes found in most aerobic 
organisms, functioning mainly in the detoxification of exogenous and endogenous compounds 
[177]. A DNA vaccine using a vector plasmid of pV4X1 containing the 26 kDa GST of S. 
japonicum (Sj26GST) resulted in a significant reduction in worm numbers and in hepatic and faecal 
eggs in vaccinated mice; when the DNA vaccine was given in combination with interleukin 18 (IL-
18), a potent IFN-γ inducing factor, the protective efficacy was improved [178]. DNA vaccines 
have some advantages over other types of immunisation but they have some limitations concerning 
the gene delivery system.  A recent study reported on a novel nanoparticle formulation of the 
Sj26GST DNA vaccine; although there was no significant reduction in worm burden, a highly 
significant decline in tissue egg burden and the fecundity of female adult worms resulted [179]. 
Toll-like receptor (TLR) 7/8 ligands (e,g. R848) and TLR 9 ligands (e,g. CpG 
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oligodeoxynucleotides, or CpG) as adjuvants can increase vaccine effectiveness  through activating 
the innate immune system and ultimately activating and directing the adaptive immune system. 
Such adjuvants have been shown to potentiate the activity of the Sj26GST DNA vaccine in mice by 
increasing splenocyte proliferation, elevating IgG, IgG2a, IFN-γ and TNFα levels, and preventing 
Treg-mediated immunosuppression [180]. In another development, Sj26GST alone, or in 
combination with fatty acid binding protein (SjFABP), expressed in recombinant pseudorabies virus 
(PRV) Bartha-K61, induced significant levels of specific immunity and protection in mice and, 
importantly, sheep, emphasising the potential effectiveness of this live vector for vaccination 
against schistosomiasis japonica in animal reservoirs [181]. 
 
1.9.2.3. Triose-phosphate isomerase (SjTPI) 
The glycolytic pathway enzyme triose-phosphate isomerase (TPI), located on the surface membrane 
of schistosomula and in most cells of adult worms, is another targeted vaccine candidate for 
schistosomiasis japonica. An early study showed that a S. japonicum (Chinese strain) TPI (SjCTPI) 
plasmid DNA vaccine (±IL-12 DNA plasmid) protected pigs against challenge infection [182]. 
Synergistic enhancement of immunogenicity and protection in mice against S. japonicum challenge 
was achieved with codon optimization and electroporation delivery of the SjTPI DNA vaccine 
[183], showing a similar level of protection as a replication-defective recombinant optimized SjTPI 
(rAdV-SjTPI) adenoviral vaccine [184] which was enhanced  using a heterologous prime-boost 
strategy [185]. A study conducted in Chinese water buffalo with a DNA vaccine encoding SjCTPI 
alone or fused with bovine HSP-70 with booster immunizations co-administered using a plasmid 
encoding IL-12, resulted in a significant reduction in worm numbers, liver and faecal eggs and in 
faecal miracidial hatching [186]. SjCTPI, delivered by a heterologous "prime-boost" regimen, has 
been used to vaccinate bovines in China as part of a multi-component integrated control package 
[165]. 
 
1.9.2.4. Insulin receptor (SjIR) 
S. japonicum possess two types of insulin receptors (SjIRs) which, on  binding to mammalian host 
insulin, can activate the parasite’s insulin pathway, which is pivotal for glucose uptake,  growth, 
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and maturation [187]. Recombinant ligands of both S. japonicum insulin receptor 1 and 2 (SjLD1, 
SjLD2), tested in vaccine/challenge trials in mice resulted in  significant reductions in faecal egg 
output, in reduced mature intestinal eggs and stunting of  adult worms [188, 189]. The retardation in 
growth of the worms likely resulted from reduced glucose uptake [188]. Furthermore, knock down 
of the SjIRs using RNA interference (RNAi)  resulted in their reduced expression coupled with a 
reduction in the transcription level of  downstream genes within the insulin pathway that are 
associated with glucose metabolism and schistosome fecundity [190].  
 
1.9.2.5. Fatty acid binding protein (SjFABP) (Sj14) 
In early studies, Sj14 generated no or only a limited level of protection [46] but when given to mice 
as a DNA vaccine with a plasmid  coding for IL-18 as adjuvant the level of protection was 
increased substantially [191]. The latter study also showed that SjFABP +IL-18 increased the Th1 
immune response by producing a higher level of IFN-γ and a lower level of IL-4 compared with 
mice vaccinated only with SjFABP [191]. Somewhat disappointedly, the Sj14 DNA vaccine, 
coupled with Sj26GST to form a bivalent DNA-based vaccine, resulted in a reduced level of 
protective efficacy [192]. 
 
1.9.2.6. 23-kDa integral membrane protein (Sj23) 
Sj23, a member of the tetraspanin family, is a 23-kDa surface-exposed S. japonicum protein 
expressed in all infective parasite stages. It was shown in BALB/c mice to elicit a rapid humoral 
immune response dominated by IgG2a antibodies, but not IgG1, and did not provide protection 
against cercarial challenge after priming with recombinant SFV RNA virus particles followed by a 
boost with recombinant protein [193]. A subsequent report of mice  vaccinated with purified 
recombinant protein LHD-Sj23-GST (large hydrophilic domain of Sj23fused with Sj26GST) in 
combination with one of three adjuvants (Freund’s adjuvant (FA), Montanide ISA 206 or 
Montanide ISA 70M), and parasite challenged, resulted in high-level production of LHD-Sj23-
GST-specific IgG1, IgG2a and IgG3 antibodies and significant reductions in worm burden [194]. In 
order to further improve on the level of protection, a multivalent DNA vaccine comprising Sj23, 
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glyceraldedyde-3 phosphate (Sj GAPDH), SjFABP and Sj26 was tested in mice which resulted in 
very high levels of protective efficacy in terms of reduced worms and liver eggs [195]. Another 
study in mice, using three cocktail DNA vaccines encoding Sj23, SjCTPI and NP30, boosted by 
electroporation in vivo and a protein vaccine boost to this regimen, resulted in a 60% reduction in 
adult worm numbers and more than 60% reduction in the liver egg burden [196]. 
Details of these and a number of other vaccine candidates tested against S. japonicum challenge 
infection are presented in Table 1.2 and elsewhere [189]. 
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Table 1. 2. Recent data on S. japonicum vaccine candidates 
Antigen Location in adult 
worm 
Identity/Function Immunization 
strategy 
Adjuvant Host Worm 
burden 
reduction 
(%) 
Liver egg 
burden 
reduction (%) 
References(s) 
Paramyosin 
(sj97) 
Schistosomulum 
surface, tegument 
and acetabular 
glands 
Binds complement and 
Fc region of IgG; 
proposed role in host 
immune evasion 
Recombinant 
proteins 
Alum or 
TiterMax 
Pig 33-34 - [197] 
Sj26GST Parenchymal 
region of male 
worm and in the  
parenchymal cells 
between the 
vitelline glands in 
the female worm 
Catalyses detoxification 
of lipophilic molecules 
by thioconjugation 
DNA vaccine - Mouse 30 
 
45 [178, 181, 
198] 
26-
kDaGST+IL-
18 
- - DNA vaccine 
 
- Mouse 49 51  
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SjGP-3 
(Sj26GST + 
PmyF3 
(fragment of 
paramyosin)) 
 
- - Polyvalent 
subunit 
CFA Mouse 41-38 26-29 
rPRV/Sj26-
KDaGST+ 
SjFABP 
- - 
Recombinant 
pseudorabies 
virus 
- Mouse 39 45 
Sheep 48 51 
Triose 
phosphate 
isomerise        
( SjTPI) 
-  
 
Glycolytic pathway 
enzyme 
     [183-186] 
- with codon 
optimiized 
version 
   
DNA vaccine 
 
 
- 
 
Mouse 
 
50 
 
57 
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-with SjTPI 
+heat-shock 
protein 70 
  DNA vaccine 
 
- Water 
buffalo 
52 61 
-with 
recombinant 
replication-
defective 
adenoviral 
vectors 
  Replication 
defective 
adenoviral 
vector-based 
- Mouse 54 52 
-with prime-
boost strategy 
 
  Adenoviral vec
tored prime 
and 
recombinant 
protein boost 
Complete 
Freunds and 
Incomplete 
Freunds 
Mouse 72 72 
S. japonicum 
insulin 
receptor (SjIR) 
SjIR-1: in the 
tegument 
membrane and 
intestinal 
epithelium of adult 
Activate the parasite’s 
insulin pathway which 
is central for glucose 
uptake, growth and 
maturation 
Recombinant 
protein 
Quil A Mouse No 
significa
nt 
reduction 
No 
significant 
reduction 
[187, 188] 
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worms 
SjIR2: Parenchyma 
in males, and in the 
vitelline glands in 
females 
Thyroid 
hormone 
receptor beta 
(SjTHRβ) 
- Interacts  with thyroid 
hormone  to modulate 
growth, development 
and differentiation, and 
metabolic processes 
Recombinant 
protein 
Montanide 
ISA 206 
Mouse 27
 
29
 
[199] 
S. japonicum 
fatty acid 
binding 
protein 
(SjFABP) 
Whole body, 
Cytosolic 
Uptake, transports and 
compartmentalizes the 
fatty acids of the host 
DNA vaccine -    [191, 192] 
-with IL-18 
 
    Mouse 38 
 
45
 
 
 
-with     Mouse 32 25 
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Sj26GST 
Twenty-three 
kilo dalton 
integral 
membrane 
protein (Sj23) 
with different 
adjuvants 
Surface-exposed Facilitates parasite 
immune regulation 
 
Recombinant 
protein 
 
Freunds Mouse 59 - [194] 
ISA206 Mouse 26 - 
ISA70M Mouse 54 - 
Tetravalent 
DNA vaccine 
(SjFABP. 
Sj23/Sj26.SjG
APDH) 
- - DNA vaccine - Mouse 71 61
 
[195] 
Cocktail DNA 
with EP and 
protein 
vaccines 
(Sj23+ 
SjCTPI+ 
- - DNA vaccine 
boosted with 
recombinant 
protein 
Complete 
Freunds 
Mouse 59 67
 
[196] 
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CDR3) 
Protein 
disulfide 
(SjPDI) 
isomerase 
Tegument as well 
as other specialized 
excretory/secretory 
(ES )organs 
Enzyme involved 
in disulfide bond 
formation and 
rearrangement and it  
interfere with the host 
immune 
Responses 
Recombinant 
protein 
Montanide 
ISA 206 
VG 
Mouse 38 33
 
[200] 
S. japonicum 
inhibitor 
apoptosis 
protein using 
adenovirus as 
live  vaccine 
vector (Ad-
SjIAP) 
 Involved in  
differentiation and 
development 
With 
recombinant a
denoviral 
vector 
- Mouse 38 32
 
[201] 
Aldose Gynecophoral Involved in antioxidant Recombinant Freunds Mouse 33 28
 
[202] 
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reductase 
(SjAR) 
canal of adult male 
worms 
defence system protein 
S.  japonicum 
Sj-F1 (using S. 
gordonii as 
live vector) 
(Sj-F1) 
Gene discovered 
when adult S. 
japonicum worm 
cDNA library was 
screened with by 
serum prepared 
against female S. 
japonicum antigens 
Unknown With S. 
gordonii as 
live vector 
- Mouse 21 35
 
[203] 
Radiation-
attenuated  
cercariae 
- - Irradiated with 
a 
60
Co source. 
- Bovines 76 81 [167, 168, 
170] 
UV-attenuated - Pigs 78 89 
Co irradiator  Miniature 
Pig 
81 - 
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1.10. New antigen discovery  
1.10.1. Immunomics  
Immunomics provides a foundation for searching critical determinants of immunity and can 
promote  antigen discovery and the design of novel vaccines for complex pathogens such as the 
schistosomes [204]. It can facilitate a systematic and comprehensive approach to antigen selection 
and prioritization for vaccine development.  For example, immunomics uses information that can be 
publicly accessed through available data banks as a primary input for epitope prediction. The 
approach applies computation for the analysis of very large and complex datasets related to multiple 
factors of protective immunity. It faces challenges associated with computational predictive 
algorithms but it provides a mechanism for advancing antigen discovery and rational  vaccine 
design for complex parasites [204]. Regarding to schistosome immunomics, the proteome and 
transcriptome have been mined to identify surface-derived proteins, a subset of which were then 
expressed and printed on a protein microarray, and then probed with antisera, details of which are 
now presented. 
 
 
1.10.2. An immunoproteomic protein microarray platform 
Despite much research in attempts to move schistosomiasis vaccine development forward, the goal 
of reaching clinical evaluation has been slow with only three molecules having reached human 
trials. Most studies have involved the use of  animal models, notably the mouse, a host recently 
questioned as a vehicle for testing vaccine candidates [48],  so similar challenges may be faced 
when clinical trials commence on new or existing candidates. Some of the challenges are risk of an 
atopic IgE response to a candidate vaccine [205], a lack of  understanding of the nature of the 
immune response and the correlates of protective immunity in humans, the transmission of other 
pathogens  in schistosomiasis endemic areas resulting in co-infected individuals which can impact 
on vaccine efficacy, and antigenic polymorphism [135].  
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The availability of a new antigen discovery pipeline would be of considerable value in order to 
identify vaccine molecules that can generate high levels of protection. It is known that migrating 
schistosomula are susceptible to immune attack but, to date, few antigens from these larvae have 
been discovered or tested as immunogens. A recent vaccinomics approach for discovering novel 
schistosome antigens that may not be revealed by conventional proteomics has involved the design 
and manufacture of an immunomics protein microarray, the first to be generated for a multi-cellular 
pathogen; mostly surface-derived proteins (215 in total) from S. japonicum and S. mansoni were 
selected, they were produced using a rapid in vitro translation system, and then printed as a vaccine 
discovery tool [206-208]. The reactivity of microarray proteins can be measured with antisera from 
human patients or schistosomiasis-resistant/exposed animals using a labelled secondary antibody 
and a laser microarray scanner; highly reactive proteins can then be assessed as putative vaccines.   
 
Antibodies from acute or chronically infected Chinese, individuals with early/advanced 
schistosomiasis japonica, and subjects exposed but stool negative for S. japonicum eggs, were used 
to screen the microarray, and this resulted in the identification of 25 immunodominant antigens, 
including a number of vaccine candidates, transporters,  tetraspanin-related proteins, and 
unannotated proteins [209]. The array has also been  screened, for IgG subclass and IgE responses, 
using sera from a human Brazilian cohort of putatively resistant (PR) and chronically S. mansoni-
infected (CI) individuals stratified by worm intensity levels (high, medium, low), determined by 
faecal egg counts, so as to identify antibody signatures reflective of protective vs. non-protective 
immune responses [210]. PR individuals generated a distinct and strong IgG1 response to a small 
set of both newly discovered and previously characterized surface antigens in contrast to the CI 
subjects who mounted strong IgE and IgG4 responses to many antigens. Probing for IgE responses 
allowed the identification of antigens that might induce potentially deleterious hypersensitivity 
reactions if used as subunit vaccines in endemic populations so it was encouraging that the PR 
individuals did not mount an intense IgE response to these antigens compared with CI subjects 
[210]. 
 
This immunomics-based approach to schistosomiasis vaccine antigen discovery was further 
validated by the identification of targets of the protective IgG1 immune response in praziquantel 
drug-induced resistant subjects exposed to S. haematobium; uncharacterized proteins and a number 
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of recognised vaccine antigens (e.g. glucose transporters, tetraspanins, glutathione-S-transferases, 
calpain) were identified [211]. The same report described the use of sera from rhesus macaques 
experimentally rendered resistant to S. japonicum infection to screen for antigen targets, and the 
discovery of new and known vaccine candidates, including many recognized by the human subjects.  
 
Another important application has been the immune screening of the schistosome microarray with 
antibody secreting cell (ASC)-probes [206, 207, 212], generated from lymph nodes draining the 
sites of larval S. japonicum migration [213]. This technique is especially advantageous for 
recognizing antigens, with low immunogenicity (selective pressure may have an influence on 
important protective epitopes which evolve over time with low immunogenicity) or those only 
temporarily exposed to the immune response [207]. In one study, ASC probes (from skin and lung) 
and sera from semi-permissive rats and sera from susceptible mice were used to screen the array 
after infection and reinfection with S. japonicum [212]. A total of 29 antigens, including a number 
of recognised vaccine candidates and several S. japonicum homologues of human schistosomiasis 
resistance markers- the tegument allergen-like proteins - were differentially recognized by infected 
hosts from which 8 proteins were prioritized as putative novel schistosome vaccine and diagnostic 
antigens [212]. In a related study, the protein microarray, screened with ASC probes generated from 
S. japonicum-infected rats, resulted in the identification of a novel antigen, termed S. japonicum Ly-
6-like protein 1 (Sj-L6L-1) which shares structural and sequence features with the Ly-6 protein 
family and has several other features suggesting it is a promising vaccine candidate against the 
developing larvae [214]. 
 
1.10.3. RNA interference (RNAi) 
In order to better understand the essential role of vaccine candidate genes in schistosome survival or 
reproduction, RNA interference (RNAi) technology has been used to silence the target genes and 
evaluate their importance for the parasite [215]. RNAi has been a major component in functional 
characterization of schistosome genes and it includes ds (double stranded)-RNA, sh (Short hairpin)-
RNA and si (short or long interfering)-RNA methods to induce transient transcriptional knock-
down. Targeting key biological functions of schistosomes such as tegumental integrity, fecundity, 
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and nutrient uptake using RNAi represent key potential sites to target the parasite for elimination 
through vaccination [216]. 
 
1.10.4. Proteomics 
Proteomics is an important and now widely used tool that can identify potential vaccine targets with 
a focus on the protein constituents of different schistosome sources such as the host-parasite 
interface comprising tegument or gut [208]. Studies on the teguments have used a number of 
procedures including biotin-labelling of live parasites and subsequent isolation and characterisation 
of the biotinylated proteins using tandem mass spectrometry (MS/MS) to identify surface-located 
proteins, and therefore those accessible to host antibodies. Proteomics of the schistosome gut and its 
contents has shed new light on the functionality of this important region of the parasite [208]. In 
short, these investigations of host proteomics coupled with other approaches such as metabolomics  
provide a mechanism to identify important clinically-relevant proteins and those having potential as 
new vaccine targets [208]. 
 
1.10.5.  Clustered regulatory interspaced short palindromic repeats (CRISPR) 
A novel genome editing tool, clustered regulatory interspaced short palindromic repeats (CRISPR), 
has been introduced recently [217]. CRISPR-Cas9 is an RNA guided endonuclease, derived from 
Streptococcus pyogenes, which mediates site-specific cleavage of double stranded DNA in diverse 
organisms resulting in knockout of target genes [218]. This technology has been applied 
successfully to the study of many free-living and parasitic organisms including Plasmodium, 
Leishmania and Cryptosporidium [217]. Although in its infancy for studying the biology of 
schistosomes,  CRISPR technology may provide a novel method for generating stable transgenic 
parasites by targeting eggs and miracidia, and for identifying specific protein-encoding schistosome 
genes implicated in schistosomiasis disease pathology and for vaccine and drug candidate discovery 
[217]. 
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1.11. Concluding comments 
 
Schistosomiasis remains a substantial public health problem due to the very high levels of 
morbidity it causes in many parts of the world. Currently, treatment is entirely dependent on PZQ 
chemotherapy. As exclusive use of the drug may lead to the emergence of drug resistant strains, 
development and deployment of a vaccine as part of an integrated approach for prevention and 
control of schistosomiasisis is to be encouraged. Much of our current understanding of immunity 
and immune mechanisms against schistosomiasis rely on studies conducted on mice, but vaccines 
based on studies performed only in the mouse model could have undesirable effects if taken 
prematurely to human clinical trials. In addition, it has been reported that a large proportion of 
penetrating cercariae fail to mature in the mouse because its pulmonary capillaries are fragile, 
raising the question as to whether this model is appropriate for vaccine efficacy studies. This 
reinforces the argument that further critical examination of any identified candidate vaccine antigen, 
whether it has foundation in acquired immunity, or not, is critical, and that moving to studies using 
larger models such as rabbits, pigs or bovines in the case of S. japonicum, or non human primates 
for S. mansoni and S. heamatobium, is clearly necessary. Furthermore, much of our knowledge 
regarding immune protection has resulted from studies focused on S. mansoni, so further studies on 
S. japonicum and S. haematobium are needed. Similarly, protection levels of many candidate 
vaccines show improvement after modification of antigen formulation and improved delivery 
systems. Combining different genes or antigens can also result in higher levels of vaccine-induced 
protection. Studies unravelling immune protection mechanisms against human and animal 
schistosomiasis should continue, as should the discovery of additional vaccine candidates using new 
approaches and techniques as they arise. Finally, funds need to be made available to allow the 
generation of a schistosomiasis vaccine antigen pipeline, as exists for many other infectious 
diseases, as well as progression of existing promising candidates into clinical trials. It is becoming 
apparent that mass drug administration alone will not eliminate schistosomiasis, and a vaccine is an 
essential component of a schistosomiasis control toolbox.  
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1.12. Rationale for the PhD program of research 
 
Increased knowledge of the immune response against schistosomiasis is pivotal to understanding 
which immune components are involved in host resistance so that an effective anti-schistosome 
vaccine can be developed. Similarly, studying the effect of a particular vaccine candidate on the 
immune response is also important because it can provide insight as to how to modulate the 
immune response in order to develop a more efficacious vaccine. Such study would also rule out 
whether vaccine efficacy data obtained in mice due to immune-based efficacy or results from 
physiological changes as there is a report that questions the use of the murine model in 
vaccine/challenge studies [48]. In particular, rigorous study on the immune response generated after 
vaccination and cercarial challenge is needed [48]. Currently, although there are number of vaccine 
candidates being developed for schistosomiasis there is limited data available on the effects of any 
vaccine candidate on T cell immunity which has been shown to be an important component of the 
immune response to the schistosome parasites. Our laboratory has targeted the ligand binding 
domain (LD1) of insulin receptors (SjIRs) and triose-phosphate isomerase (SjTPI) as putative 
vaccine candidates against schistosomiasis japonica with both molecules, as recombinant proteins, 
inducing encouraging protection in mice. Accordingly, this project considered whether combining 
the two recombinant proteins as antigen mix (rSjTPI-LD1) would generate a more pronounced 
immune response and could yield improved protective efficacy.  
 
1.13. Aims 
The aims of the project were to examine the T cell immune response against S. japonicum infection 
in the mouse, and to determine the effects of the antigen mix, rSjTPI-LD1 vaccine on T cell 
immunity against the parasite. 
 
 1.14.  Hypothesis 
 
As S. japonicum infection induces a Th1/Th2 immune balance, we hypothesized that vaccination 
with the rSjTPI-LD1 vaccine would alter the immune response to produce a more protective Th1 
response. 
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1.15. Objectives   
The study  had  three phases. The objectives in each phase were as follows:       
 
 Phase 1 (Chapter 2) 
To examine  T effector ( Th1,Th2 and Th17) and regulatory T cell  immune responses to  
schistosomal adult worm antigen preparation (SWAP) and schistosomal soluble egg antigen (SEA) 
in S. japonicum-infected CBA mice.  
 
 
Phase 2 (Chapter 4) 
To evaluate  T effector ( Th1,Th2 and Th17)  and regulatory immune responses  to the multivalent 
recombinant protein vaccine (rSjTPI-LD1) antigen in naïve but immunized CBA mice.  
     
 Phase 3 (Chapter 5) 
 To evaluate T effector (Th1, Th2 and Th17) and regulatory immune responses to S. japonicum 
infection in mice immunized with the multivalent recombinant protein vaccine antigen (rSjTPI-
LD1). 
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                                                   Chapter 2 
  T cell mediated immunity in CBA mice during S. japonicum infection 
 
2.1. Introduction to  paper 
 
The aim of this study was to examine T effector (Th1,Th2 and Th17) and regulatory T cell  immune 
responses in  S. japonicum-infected CBA mice. This chapter consists of a peer-reviewed manuscript that was 
resubmitted in the journal of  Experimental Parasitology. 
 
Biniam Mathewos Tebeje, Marina Harvie, Hong You, Vanessa Riverra and Donald P. McManus. 
T cell mediated immunity in CBA mice during Schistosoma japonicum infection.  
 
2.2. Contribution of candidate 
 
Professor Donald P. McManus, Dr. Marina Harvie and Dr. Hong You conceived and designed the 
research. I performed all of the experiments in collaboration with Dr. Marina Harvie and Miss 
Vanessa Riverra. I performed all of the data analysis. I was involved in data interpretation in 
consultation with Dr. Marina and Dr. Hong You. I prepared the draft manuscript. I revised the 
manuscript based on reviewers comments and suggestions and prepared a response to the reviewers. 
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2.3. T cell mediated immunity in CBA mice during S. japonicum infection 
 
Biniam Mathewos Tebeje1, 2*, Marina Harvie1, Hong You1, Vanessa Rivera1 and Donald P. 
McManus1* 
1 Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, 
Queensland, Australia, 300 Herston road, Brisbane city QLD 4006 
 
2 School of Public Health, University of Queensland, Brisbane, Australia; 
 
2.4. Abstract  
 
Characterisation of the cellular immune response to schistosomiasis is well established for 
Schistosoma mansoni but a comprehensive description of T cell-mediated immune responses 
against S. japonicum infection is lacking.  Accordingly, 20 CBA mice were infected with cercariae 
of S. japonicum and the immune response at different time points was determined. Mouse spleen 
and liver lymphocytes were isolated from the mice and stimulated with schistosomal adult worm 
antigen preparation (SWAP) and schistosomal soluble egg antigen (SEA). There was a relatively 
higher Th1 immune response to SWAP compared to SEA at the early phase of infection (up to 
week 5 post challenge). However, a Th2 immune response directed against SEA was dominant at 
week 6 post-infection, a time point when the highest IgG response against both SWAP and, 
especially, SEA was generated. The regulatory immune response was highest at the early phase of 
the immune response (upto week 5 post challenge) followed by a rapid decline at week 6-post 
infection. Before egg-laying, S .japonicum induced a regulatory T cell immune response which may 
limit the early Th1-mediated immune response that is believed to be protective in murine 
schistosomiasis. Following egg laying, the immune response was polarized to a Th2 immune 
response mainly directed against the eggs and this may contribute to parasite survival. 
Keywords: Schistosomiasis, Cell mediated immunity, T lymphocyte, Th1, Th2, Regulatory T cells 
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2.5. Introduction 
 
schistosomiasis is a chronic parasitic disease and the cause of significant residual morbidity; 
consequently it is of considerable public health importance, having substantial socioeconomic 
impacts on many impoverished communities [219]. Human infection is caused by five main species, 
namely Schistosoma mansoni, S. japonicum, S. mekongi, S. intercalatum and S. haematobium; the 
latter causes urogenital disease [1]. and the others are responsible for intestinal and hepatic 
schistosomiasis [3, 220]. The pathogenesis in schistosomiasis is due mainly to the immunological 
response against schistosome eggs [221]. Many previous studies on the immunology of 
schistosomiasis showed that a Th1 polarized immune response occurs at the early phase of infection 
followed by switch to a Th2-type response [19]. However, this model has only been clearly 
demonstrated with Schistosoma mansoni but a full and detailed description of the Th1-Th2 shift in 
regard to S. japonicum infection is lacking although the currently available information suggests 
that this paradigm broadly holds true for this species as well [222, 223]. In contrast to infection with 
S. mansoni, neutrophils have been implicated as the main cell type involved in hepatic 
granulomatous pathology in schistosomiasis japonica [224] and higher egg output (at least four 
times greater) and greater severity of immunopathology are  also observed [225]. Thus, even though 
both schistosomes likely share many common antigenic determinants, it is probable that there are 
unique species-specific antigens which led early investigators to suggest there are differences in the 
host immune response to the two blood flukes [226, 227].  
 
 
A recent study [222] showed that the Th1-Th2 shift appears to operate in the low pathology 
C57BL/6 mouse strain infected with S. japonicum [222]  but, to our knowledge, it is not known 
whether the shift occurs in the high pathology CBA mouse which exhibits a stronger splenic 
proliferative response and a lesser suppressor T cell response after a patent schistosome infection 
[154, 228]. Therefore, we sought to analyse the immune responses generated in CBA mice during 
the course of infection with S. japonicum particularly as this mouse strain has been used widely in 
schistosomiasis vaccine trials to screen vaccine candidates [188, 229-234]. 
 
 
Until recently, Th1 and Th2 cells were considered the predominant T cells involved in the immune 
response to schistosomiasis. However, following the discovery of T helper 17 cells (Th17) [235], a 
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subset of pro-inflammatory T helper cells defined by their production of interleukin 17 (IL-17), 
there has been a paradigm shift from the CD4
+
 Th1/Th2 cell paradigm to include Th17, and 
endeavours to uncover the role of Th17 cells in schistosome immunity, especially in relation to the 
development of schistosomiasis immunopathology. Limited studies with C57BL/6 mice showed 
that generally that there was a correlation between a high level of IL-17 and disease severity [68, 
236-238]. A limitation of much research conducted to date on the immunology of schistosomiasis 
has been the dependence on the C57BL/6 mouse [67], due to the availability of various genetically 
modified strains on this background. Accordingly, studies on the Th1–Th2 shift and the 
involvement of Th17 in murine schistosomiasis japonica with other mouse strains such as high 
pathology CBA mice are limited or have not been undertaken. Such studies are very important in 
that a wider view of the area will help further understanding of the host immune response to 
schistosomiasis.   
 
  
Studies, mainly focussing on S. mansoni, showed that naturally occurring regulatory T cells (Tregs) 
play an essential role in the immune response to schistosomiasis by controlling both Th1 and Th2 
effector cells [239-241] but there are conflicting reports on the precise mechanism involved. For 
example, one study report revealed that Tregs could suppress Th2 cytokine production in C57BL/6 
mice induced by immunization with S. mansoni eggs [242]. In contrast, another study showed that 
Tregs brought about Th2 polarization by inhibiting the Th1 immune response [243]. As knowledge 
on Tregs in schistosomiasis japonica is limited, we sought to determine the effector and regulatory 
T cell immune responses in CBA mice at different time points following S. japonicum infection 
(Figure 2.1). 
 
2.6. Materials and methods 
2.6.1. Ethics Statement 
The conduct and procedures involving animal experimentation were approved by the Animal Ethics 
Committe of QIMR Berghofer Medical Research Institute (project number 288 and ethics ID 
A0108-054). 
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2.6.2. Parasites 
Oncomelania hupensis hupensis, naturally infected with S. japonicum, were obtained from an 
endemic area in Anhui Province, PR China, and transported to the QIMR Berghofer Medical 
Research Institute in Australia. Cercariae were shed from the infected snails and collected as 
described [244]. Briefly, infected snails were exposed to light for 3-4 hours. A 10 μl bacteriological 
loop was used to collect the cercariae from the water suface. 
 
2.6.3 Mice 
Twenty female CBA mice (6–8 weeks old) were anaesthetised by intraperitoneal injection (IP) with 
ketamine (100mg/kg) and Xylazine-20 (30 mg/kg), their abdomens were shaved  and exposed for 
40 minutes to 34 S. japonicum cercariae. Five CBA mice were culled and perfused with PBS at 
weeks 3, 4, 5 and 6 post-challenge infection (Figure 2.1). Briefly, the culled mice were perfused  by 
injection of sodium citrate buffer into the inferior vena cava and worms were collected from an 
incision in the portal vein.  Fifty μl of blood was collected from each mouse by tail bleed prior to 
culling. The livers and spleens of the individual mice were collected for cell isolation.In addition, a 
section of  liver was excised from each mouse and used for liver egg counts. Five additional naive 
mice were also used as controls.  
 
2.6.4. Blood collection 
Fifty μl of blood were collected from the CBA mice at the different time points (one day before 
culling the mice). The mice were first warmed in order to widen their blood vessels and the 
collected blood was allowed to fully clot and then was centrifuged at 3000g for 5 minutes. 
Eventually the collected serum was stored at -80
0
C until required. 
 
2.6.5. Worm and liver egg counts     
Adult S. japonicum worms were collected by perfusion at weeks 4, 5 and 6 post infection and the 
total worm count and worm pair numbers were determined. Liver egg counts were performed to 
determine the number of eggs per gram (EPG) in the liver as described [245]. Briefly, a weighed 
liver portion was digested with 4% (w/v) KOH and incubated overnight at 37
0
C. Then the 
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homogenate was centrifuged at 2000g for 10 minutes, washed with 4% KOH (w/v), the supernatant 
was discarded and the pellet containing eggs was resuspended and fixed in 10% (v/v) 
paraformaldeyde. Counting of the eggs was performed four times for each sample and the average 
was taken to calculate the liver EPG. 
 
Figure 2.1. Different time points where the immune response was determined after CBA mice 
were challenged and infected with S. japonicum. At each time point, five challenged mice were 
culled, perfused, worms were collected, and the spleen and liver harvested. Five unchallenged mice 
were used as controls. 
 
2.6.6 Adult worm soluble antigen preparation (SWAP) 
Freshly perfused adult worms of S. japonicum were washed with Tris buffer PH 7.4, homogenised 
for 5 minutes on ice using a motor cord-less homogeniser (Kimble Chase, Rochester, NY, USA), 
and the homogenate was then centrifuged at 16,000g [246] for 30 minutes and the supernatant was 
used as SWAP. Protein concentration was measured by standard Bradford protein assay (Biorad, 
Hercules, CA, USA) using bovine serum albumin as standard. 
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2.6.7. Soluble eggs soluble antigen (SEA) 
Livers from mice infected with S. japonicum were chopped and digested with 100 mg/ml 
Collagenase B (Roche, Mannheim, Germany) overnight at 37
0
C on a rocker. Following washing by 
spinning at 2000 rpm for 5 minutes and resuspending with ice cold 1× PBS, the preparation was 
passed through 250μm and 150μm sieves. The isolation of eggs was achieved by centrifuging the 
preparation at 3000rpm for 5 minutes over a percoll (MA, USA)-0.25M sucrose gradient [247]. The 
isolated eggs were homogenized in PBS, examined under a microscope to confirm they were 
completely disrupted, centrifuged at 10,000g for 2 hours at 4
0
C and the supernatant was used as 
SEA. Protein concentration was measured by standard Bradford protein assay.  
 
2.6.8. Lipopolysaccharide (LPS) removal from  SWAP and SEA  
LPS removal from SWAP and SEA was undertaken using Triton X-114 (Sigma-Aldrich, St Louis 
USA) as described [248]. Briefly, 1% Triton X-114 was added to the SWAP or SEA preparations 
and the mixture was incubated for 30 minutes at 4
0
C on a wheel shaker, followed by 10 minutes 
incubation at 37
0
C. The samples were then centrifuged at room temperature at 20,000×g for 10 
minutes and the upper aqueous phase containing the SWAP or SEA preparation was retained. 
Residual endotoxin removal was confirmed using a Pierce LAL Chromogenic Endotoxin 
Quantitation Kit (Thermo Scientific, Rockford, USA) according to the manufacturer’s instructions. 
 
2.6.9. Enzyme-linked immunosorbent assays (ELISAs) 
One hundred μl of 1μg/ml of SWAP or SEA in buffer (Bicarbonate buffer PH 9.6) were coated 
separately on immunoplates (NUNC, Roskilde, Denmark) at 4
0
C overnight. The plates were 
blocked with 5% (v/v) skim milk in PBS for an hour at 37
0
C and then washed 3 times with PBS 
containing 0.05% (v/v) Tween 20 (PBST). Mouse serum samples, serially diluted (1:100-1:12,800) 
with 5% (w/v) skim milk in PBST (100μl/well), were added to the plates which were incubated at 
37
0
C for 2 hours. Sheep anti- mouse IgG antibody conjugated with peroxidise (diluted 1: 20, 000), 
used as secondary antibody, was added to the plates which were incubated for 1 hour at 37
0
C. PBST 
washes were applied five times after each step, 2 minutes between each wash. Finally, reactions 
were developed with 3,3′,5,5′- tetramethylbenzidine substrate solution (TMB) (Aldrich, St Louis, 
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Mo, USA) (100μl/well) for 5 minutes and stopped using 2N sulphuric acid (50 μl /well). A 
microplate reader was used to read optical density (OD) at 450nm from all serum samples that were 
run in duplicate. A positive test result was defined when the OD values was greater than two times 
the mean of OD value obtained with serum samples from control mice. 
        
2.6.10. Spleen and liver lymphocyte preparation and stimulation 
 
Spleens were gently pressed through a 70μm cell strainer to produce a single cell suspension. Red 
blood cells were removed from the cell suspension using RBC lysis buffer (Sigma, St.Louis, MO, 
USA), before it was washed and resuspended in Iscove’s Modified Dulbeccco’s Medium (IMDM; 
Gibco,Grand Island, NY,USA)  to enable counting of viable cells.  
 
 
Mouse liver was chopped and then digested with 5 ml collagenase (5 mg collagenase Type IV 
(Sigma), 5 mL Hank's balanced salt solution HBSS (Sigma) and 200 µg DNase (Sigma)) and the 
preparation was then pressed through 100μm cell strainers. The filtered solution was then washed 
with 2% (v/v) foetal bovine serum in phosphate buffered saline (FBS/PBS), the sedimented pellet 
resuspended and Percoll density gradient medium added. Then the suspension was centrifuged at 
1700 rpm for 12 minutes at room temperature. The resulting supernatant containing hepatocytes, 
debris and the Percoll medium was discarded, the pellet was resuspended in 1ml of RBC lysis 
buffer (Sigma) and the preparation was incubated for 5 minutes at room temperature. Then,  9 ml of 
(2% v/v) FBS/PBS was added, the preparation was centrifuged at 1200 rpm for 6 minutes at 4
0
 C, 
the supernatant  discarded and the pellet  resuspended in IMDM.  
 
 
The purified spleen and liver cells were counted and their viability assessed using the trypan blue 
exclusion method [249]. Once counted, cells were resuspended at a concentration of 5 x 10
6
/mL and 
used to plate flat bottom 96 well plates. The cells were stimulated separately with 10μg/ml SEA and 
SWAP and 0.5 μg/ml Con A as a positive control and IMDM medium only was added to cells 
plated as a negative control. After cell culture for 68 hours, Brefeldin A (BFA), at a final 
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concentration of 200 µg/ml, was added to the plates. Cells were harvested 4 hours after the addition 
of BFA.  
 
2.6.11. Flow cytometry 
2.6.11.1. Effector T cell assessment 
Cells were first surface stained with Brilliant Violet 421 conjugated anti CD3 (Clone 17A2, 
Biosearch, CA, USA), Alexa Fluor 700 conjugated anti-CD4 (Clone: RM4-5, BD Bioscience, New 
Jersey, USA), Brilliant Violet 650 conjugated anti-CD8 (Clone: 53-6.7, Biosearch) and Alexa Fluor 
488 conjugated anti-gamma delta (γδ)TCR (Clone: GL3, Biosearch). Following washing with 2% 
(v/v) FBS, cells were fixed by fixation/permeabilization solution (BD Biosearch) and washed with 
BD perm/wash (BD, Biosciences). Intracellular staining was performed using PerCpCy5.5 
conjugated anti-IFN-γ (Clone: XMG 1.2, Biosearch), Phycoerythrin (PE)-CF594 conjugated anti-
IL-4 (Clone: 11B11, BD Bioscience) and Alexa Fluor 647 conjugated anti-IL-17 (Clone: TC11-
18H10.1, Biosearch).  
 
2.6.11.2. T regulatory cell assessment 
Cells were first surface stained with Brilliant Violet 421 conjugated anti CD3 (Clone: 17A2, 
Biosearch), Alexa Fluor 700 conjugated anti-CD4 (Clone: RM4-5, BD Bioscience) and PerCP5.5 
conjugated anti-CD25 (Clone: PC61, BD Bioscience).  Following washing with 2% FBS, cells were 
fixed by transcription factor (TF) Fix/Perm buffer (BD Bioscience) and washed with BD TF 
perm/wash (BD, Biosciences). Intracellular staining was performed using PE-CF594 conjugated 
anti FoxP3 (Clone: MF23, BD Bioscience). 
 
Fixable viability stain 780 (BD, Horizon TM), for discrimination of viable from non-viable cells 
and purified rat anti-mouse CD16/CD32 (mouse CD Fc Block TM) (2.4G2, BD Pharmingen) for 
blocking nonspecific binding, were used for both effector T cell and regulatory T cell assessment. 
Fluorescent Minus One (FMO), single stained cells and anti-rat and anti-hamster Ig k and negative 
control compensation beads (BD, Bioscience) were also prepared to act as controls and to allow for 
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fluorochrome compensation. The stained cells were analysed using Fortessa 4A and FACS Diva 
software (BD, Bioscience). Analysis of the data was carried out using Flowjo version 10 software. 
 
2.6.12. Gating strategy 
The gating strategy to analyse the flow cytometry data are shown in Figures 2.2., 2.3. and 2.4. 
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Figure 2.2. Gating strategy of CD4
+
 and CD8 
+
 cells and intracellular cytokines. 
 
 
 
 
Figure 2.3. Gating strategy of gamma delta T cells (γδ T cells) (CD3+ CD4 -CD8- γδTCR+ ) and 
intracellular cytokines. 
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Figure 2.4. Gating strategy of Tregs (CD3
+
 CD4
+
 CD25
+
 FoxP3
+
). The percentage of Tregs 
was estimated from the total number of CD4
+
 T cells. 
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2.6.13. Statistical analysis 
All data are presented as the mean ± SEM. Flow cytometric dare were acquired by BD LSRFortessa 
4A and analyzed using FlowJo (Version 10). Two-tailed t-test was used to assess the differences 
between the groups. A statistically significant difference for any comparison was considered as P 
value ≤ 0.05. Nonparametric Mann-Whitney test was used to determine the significant differences. 
GraphPad Prism software (Version 7.02) was used for analysis and generating figures. For Flow 
cytometric data, percentage/ frequency of events of characteristic markers and intracellular cytokine 
expression were used as a base for all comparisons. 
2.7. Results 
2.7.1. Worm and egg burdens in S. japonicum-infected CBA mice 
CBA mice infected with S. japonicum were perfused at weeks 3, 4, 5 and 6 post-infection and 
worms were collected and counted. A small number of immature worms were observed at 3 weeks 
post-infection. At week 6 post-infection, the average total number of worms and worm pairs were 
27+2 and 12+2, respectively. Liver egg burdens at weeks 5 and 6 showed a consistent and 
significant increase over the course of infection, compared with that of week 4 post-infection 
(Figure 2.5). 
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Figure. 2.5. Liver egg burden in S. japonicum-infected CBA mice. At each time point post-
challenge infection, five infected CBA mice were culled and perfused. The number of eggs per 
gram of liver are shown. Data are representative of two independent experiments. The error bars in 
the panels represent the standard error of the mean (SEM). P values were determined using t-tests to 
compare the number of eggs per gram of liver at different weeks.   
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2.7.2. Increased cell numbers in the spleen and liver after S. japonicum infection 
Isolation and counting of immune cells from the spleen and liver of infected and control mice 
revealed the total number of the cells per ml of single cell suspension in both organs significantly 
increased in S. japonicum-infected animals over the course of the  infection (Figure 2.6). 
 
 
Figure. 2.6. Number of immune cells in S. japonicum-infected CBA mice at different time 
points post-infection. At each time point, five infected mice were culled and the spleens and livers 
removed; five naive mice were used as controls. Data are representative of two independent 
experiments. *=p value ≤ 0.05, **=p value ≤0.001. (A) Number of splenocytes   (B) Number of 
liver lymphocytes 
 
 
2.7.3. The serum IgG response is higher against egg-derived antigens than against adult 
worm-derived antigens 
Generally, there was a trend of increased IgG response against both SWAP and SEA in the sera of 
mice over the course of the infection.  At week 6 post-infection, the IgG response was significantly 
more pronounced (p= 0.0159) against SEA (titre of 1: 3200) than SWAP (titre of 1:200) in infected 
animals; at weeks 5 and 6 post-infection, the IgG response against SEA was significantly higher 
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(p=0.0357) than uninfected controls and there was a significant increase in IgG level from week 5 
to week 6 (p=0.0079) against SEA (Figure 2.7). 
 
 
Figure. 2.7. Levels of anti-SWAP and anti-SEA-IgG antibodies determined by ELISA in sera 
from S. japonicum-infected CBA mice at different time points post-infection and from 
uninfected control animals. At each time point, blood was taken from five S. japonicum infected 
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mice and five naive (uninfected) animals. The OD values determined for anti-SEA and anti-SWAP 
IgG serum antibodies at different time points were compared; *p< 0.05 is significant. SWAP-
ELISA: Schistosome soluble adult worm antigen preparation-enzyme-linked immunosorbent assay; 
SEA-ELISA: Schistosome soluble egg antigen-enzyme-linked immunosorbent assay. Data are 
representative of two independent experiments. *=p value ≤ 0.05, **=p value ≤0.001. 
 
2.7.4. The Th1 immune response is higher during the early phase S. japonicum infection 
 
The percentage of CD4
+ 
T splenocytes producing IFN-γ increased significantly (p=0.0079) up to 
week 5 post-infection but this was followed by a dramatic decrease by week 6 (Figure 2.8.A and 
Figure 2.9.A). The highest proportion of IFN-γ-producing CD4+ splenocytes was observed when 
cells were stimulated with SWAP (Figure 2.8.A).  
 
The production of IFN-γ by liver CD4+  lymphocytes after culture with SEA and SWAP declined 
substantially at week 6 post-infection, similar to that observed with the splenocytes, following a 
significant increase at week 5 post infection (Figure 2.8.B and Figure 2.9.B). However, the 
proportion of IFN-γ-producing liver lymphocytes was highest when restimulated with SEA (Figure. 
2.8.B). 
 
Figure. 2.8. kinetics of IFN-γ producing CD4+ splenocytes and liver lymphocytes of S. 
japonicum-infected CBA mice at different time points post-infection following stimulation 
with different antigens in vitro. (A) The change in percentage of IFN-γ-producing CD4+ 
splenocytes (Th1 cells) over the course of the infection.  (B) The change in percentage IFN-γ-
producing CD4
+
 liver lymphocytes (Th1 cells) over the course of the infection. Data are 
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representative of two independent experiments. Statistically significant differences between 
percentages of IFN-γ producing CD4+ cells at different time points post challenge from challenged 
mice compared with the cells from naïve control mice. (*=p value ≤ 0.05, **=p value ≤0.01). *=p 
value ≤ 0.05, **=p value ≤0.001). The p value in the figure represents for cells restimulated with 
SWAP (Figure A) and with SEA (Figure B). 
 
      
                                                           
 
Figure 2.9. Flow cytometry analysis of IFN-γ-producing splenocytes and liver lymphocytes 
(Th1 cells) of CBA mice at different time points post S. japonicum infection. (A) Flow 
cytometry data showing percentage changes of Th1 (CD3
+
 CD4
+
 IFNγ+) cells in the spleen of 
infected mice at different time points. (B) Flow cytometry chart showing percentage changes of Th1 
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(CD3
+
 CD4
+
 IFNγ+) cells in the liver of infected mice at different time points. The percentage of 
INF-γ- producing cells in both panels was estimated from the total number of CD4+ T cells.  
 
 
2.7.5. A Th2 immune response follows egg-laying by S. japonicum 
 
Unlike IFN-γ-producing splenocytes, the percentage of IL-4 producing CD4+ splenocytes showed a 
slightly decreasing trend at the early phase of S. japonicum infection but a significant increase 
(p=0.01360) in percentage of these cells occurred at week 6 post-infection (Figure 2.10. A; Figure 
2.11.A; and Figure 2.12.A). This time point coincided with the highest egg burden in the liver, 
likely correlating with a Th1/Th2 shift. The highest proportion of IL-4-producing CD4
+
 splenocytes 
occurred when these cells were stimulated with SEA (Figure 2.10.A).  
 
 
The trend of percentage of IL-4 producing liver lymphocytes was similar to that of splenocytes in 
that we observed a low level  up to week 5 followed by a sharp increase by week 6 (Figure 2.10.B; 
Figure. 2.6. C; Figure. 2.11. B; Figure. 2.12. B). 
 
 
 
Figure 2.10. kinetics of IL-4 producing cells by S. japonicum-infected CBA mice at different 
time points post-infection following stimulation with different antigens in vitro. (A) Change in 
IL-4  producing CD4
+
 splenocytes (Th2 cells) over the course of infection.   (B) Change in IL-4-
producing CD4
+
 liver lymphocytes (Th2 cells) over the course of infection. (C) Change in IL-4-
producing CD8
+
 liver lymphocytes (Th2 cells) over the course of infection. Data are representative 
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of two independent experiments. Statistically significant differences between percentages of IL-4 
producing CD4
+
 cells at different time points post challenge from cells of the challenged mice 
compared with cells from naïve control mice. *=p value ≤ 0.05, **=p value ≤0.001. The p value in 
the figure represents cells restimulated with SEA. 
 
 
 
Figure 2.11. Flow cytometry analysis of IFN-γ producing cells (Th1) and IL-4 producing cells 
(Th2) at different time points post-S. japonicum infection of CBA mice. The histogram shows 
the percentage change of Th1 and Th2 cells over the course of the S. japonicum infection in CBA 
mice. (A) Frequency of CD4
+
 splenocyte producing IFN-γ (Th1 cells) and IL-4 (Th2 cells). (B) 
Frequency of CD4
+
 liver lymphocytes producing IFN-γ (Th1 cells) and IL-4 (Th2 cells). Data are 
representative of two independent experiments. Statistically significant differences between 
percentages of IFN-γ producing cells (Th1) or IL-4 producing CD4+ cells (Th2) at different time 
points post challenge compared with cells from naïve control mice. *=p value ≤ 0.05, **=p value 
≤0.001.*=p value ≤ 0.05, **p= value ≤0.001. 
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Figure 2.12. Flow cytometry analysis of IL-4-producing splenocytes and liver lymphocytes 
(Th2 cells) of CBA mice at different time points post-S. japonicum infection. (A) Flow 
cytometry data showing percentage changes of Th2 (CD3
+
 CD4
+
 IL-4
+
) cells in the spleen of 
infected mice at different time points. (B) Flow cytometry chart showing percentage changes of Th2 
(CD3
+
 CD4
+
 IL- 4
+
) cells in the liver of infected mice at different time points. The percentage of IL-
4- producing cells in both panels was estimated from the total number of CD4
+
 T cells. 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
2.7.6. Gamma delta T cells (γδ T cells )  are the major cells producing IL-17 in the liver 
 
The frequency of IL-17-producing CD4
+
 cells in both splenocytes and liver lymphocytes 
consistently increased over the course of the S. japonicum infection (Figure 2.13.A and Figure 
2.13.B). However, γδ T cells producing IL-17 were with the highest percentage than other cells and 
similar to CD4
+
 cells, they generally showed a consistent increase over the course of the infection 
with a sharp increase at week 6 post-infection (Figure. 2.13. B; Figure. 2.13.C). Furthermore, a 
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higher proportion of IL-17- producing cells was found in the liver (18%) compared with the spleen 
(2%) (Figure 2.13.A; Figure. 2.13.C).  
 
 
 
Figure 2.13. Kinetics of IL-17-producing cells in S. japonicum-infected CBA mice at different 
time points post-infection following stimulation with different antigens in vitro. Data are 
representative of two independent experiments. *=p value ≤ 0.05, **=p value ≤0.001. (A) Change 
in IL-17-producing CD4
+
 liver lymphocytes (Th17 cells) over the course of infection.  (B) Change 
in IL-17-producing CD4
+
 liver lymphocytes (Th17 cells) over the course of infection. (C) Change 
in IL-17 -producing liver γδ T cells over the course of infection (CD3+ CD4- CD8- γδTCR+). 
Statistically significant differences between percentages of IL-17 producing CD4
+
 cells at different 
time points post challenge from challenged mice compared with naïve control mice. *=p value ≤ 
0.05, **=p value ≤0.001. The P value in the figure represent indicated for the cells restimulated 
with SEA. 
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2.7.7. The regulatory T cell immune response is higher during the early phase of infection 
There was a significant increase (p=0.0079) in the frequency of regulatory T splenocytes over the 
course of the infection but a significant decrease (p=0.0079) occurred at week 6 post-infection 
(Figure 2.14.A and Figure 2.15). Examination of the regulatory T cell immune response in the 
liver was not undertaken at weeks 3 and 4 post-infection due to the low number of immune cells at 
these time points but a decrease in the number of regulatory T cells was observed from week 5 to 6 
post-infection (Figure 2. 14. B). 
 
 
 
 
Figure 2.14. Kinetics of regulatory T splenocytes in S. japonicum-infected CBA mice over the 
different time points following stimulation with different antigens in vitro. (A). Change in 
percentage of regulatory T cells (CD3
+
 CD4
+
 CD25
+
 FoxP3
+
) in the spleen over the course of 
infection. (B). Change in percentage of regulatory T cells (CD3+ CD4+ CD25+ FoxP3+) in the liver 
over the course of infection. Statistically significant differences between percentages of Tregs 
restimulated with SEA (labelled with red) at different time points post challenge compared with 
sera from naïve control mice. *=p value ≤ 0.05, **=p value ≤0.001. Data are representative of two 
independent experiments.  
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Figure 2.15. Flow cytometry chart showing percentage changes of regulatory T cells (CD3
+
 
CD4
+
CD25
+
FoxP3
+
) in the spleen of CBA mice at different time points post-S. japonicum 
infection. The percentage of regulatory T cells was estimated from the total CD4
+
 T cells present. 
Five naive mice were used as controls. 
 
 
2.8. Discussion 
 
Experimental helminth models have shown how the interaction between Th1, Th2, Th17 and 
regulatory T cells (Tregs) can affect resistance to infection [250, 251]. Accordingly, we examined 
the effector T cell and regulatory T cell immune responses in the spleen and liver of CBA mice at 
different time points post-infection with S. japonicum. In general, there was an increase in the 
number of splenocytes and liver immune cells over the time course of the infection. There was a 
consistent increased Th1 immune response up until week 5 post-infection and it was higher against 
the adult parasite derived protein (SWAP) than egg derived protein (SEA) suggesting the immune 
response was directed primarily against the worms (Figure 2.8.A). However in the liver the Th1 
immune response was higher against egg derived protein (SEA) than the adult parasite derived 
protein (SWAP) (Figure 2.8B). The Th1 immune response observed at the early phase of the 
infection may be targeting killing of the schistosomulum stage as it has clearly been shown 
previously that the Th1 response in murine schistosomiasis is crucial in killing these larvae and/or 
the adult parasites by inducing macrophages and B cells to produce complement fixing and 
opsonising antibodies which eventually result in host resistance [222, 252-256]. However, in the 
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current study, the Th1 immune response declined sharply at week 6 post-infection, a time point 
when considerable numbers of eggs are being laid, and was replaced by a Th2 immune response, a 
finding in concordance with other studies showing a Th1/Th2 shift after both S. japonicum and S. 
mansoni infections in mice [19, 222, 257].  
 
 
The increased Th2 response may be triggered by the increased numbers of eggs trapped in the liver 
at week 6 post-infection as the immune response was higher against SEA than SWAP (Figure 2.10) 
and there was also high liver egg burden at this time point (Figure 2.5.C). Such a polarized Th2 
immune response may lead to hepatic pathology and favour the development of pathogenic IgE 
[254]. It is clear that a Th2 type of immune response induces humoral immunity by inducing the 
production of IgG1 [250]. The current study also demonstrated that there was a consistent increase 
in IgG titre over the time course of the S. japonicum infection with a sharp increase at week 6 post-
infection. Moreover, a significantly higher IgG response was observed against the egg-derived 
antigen (SEA) than worm-derived antigen (SWAP) indicating the predominant Th2 immune 
response is directed against parasite eggs.  
 
 
Even though there was a trend towards an increased Th1 immune response at the early phase of 
infection (up to week 5 post-infection), the frequency of IFN-γ-producing cells (marker of a Th1 
immune response) was lower compared with the generated Th2 immune response at the later phase 
of the infection. This may be the reason why most of the S. japonicum schistosomula were able to 
survive and mature into adult parasite (more than 70% of the cercariae used to infect the CBA mice 
were recovered as adult worms) (Figure 2.5.A). Moreover, we also demonstrated a trend of 
increasing T regulatory immune response at the early phase of infection which likely suppressed the 
potentially parasite-damaging Th1 immune response [250, 255, 258-262]. Similar to the current 
report, there is some prior evidence that schistosomes can induce Tregs. Sm29, a membrane-bound 
glycoprotein found on the tegument of S. mansoni, with homology to some unknown S. japonicum 
proteins, has been shown to increase the production of immune regulatory cytokines, particularly 
IL-10, which can inhibit the Th1 immune response [263]. However, in contrast, another study 
showed that FoxP3
+
 Treg cells did not play a prominent role in regulating immunity to S. mansoni 
larvae, [264]; consequently, the different factors accounting for these contradictory findings require 
further investigation. 
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Surprisingly, there was a sharp decline in Treg cells at week 6 post-infection in both the spleen and 
liver which may have contributed to the increased Th2 immune response at this time point. This 
type of unregulated Th2 immune is one of the reasons for the severe fibrosis characteristic of 
murine schistosomiasis [265]. There is also evidence showing that a deficiency of Tregs can result 
in immunopathology and that CD25
+
 Tregs can prevent this immunopathological response directed 
against eggs [240, 250, 266]. The reasons why this phenomenon (high Th2 immune response with 
low Treg response) was observed in the present study may be because: a) High pathology CBA 
mice were used rather than the more common C57BL/6 strain in which pathology is less severe 
[267]; and b). The CBA mice were infected with a relatively high cercarial dose (34) of S. 
japonicum resulting in a higher liver egg burden and a more pronounced chronic infection than 
reported in other studies.  
 
 
We additionally examined the IL-17 mediated immune response against S. japonicum and found a 
consistent increase in the percentage of IL-17 producing cells over the time course of the infection 
in both the spleen and liver. This IL-17-mediated immune response could have been directed 
against S. japonicum eggs trapped in the liver [67, 268]. IL-17 also plays an important role in 
contributing to the granulomatous inflammatory and fibrosing reactions in schisotosome-infected 
mice [68, 238]. Moreover, IL-17 mediated immunity and the Th2 immune response recruit 
eosinophils and neutrophils, respectively, for the formation of liver granulomas [251].  In the 
present study, the main IL-17 producing cells in the liver were gamma delta T cells and a sharp 
increase in the numbers of these cells was observed at week 6 post-infection, supporting a previous 
study with S. japonicum-infected C57BL/6 mice [68].  
 
 
In summary, we demonstrated a Th1/Th2 shift in the immune response over the course of a S. 
japonicum infection in CBA mice which is similar to the immune response against S. mansoni. 
Moreover, we showed a significantly high involvement of gamma delta T cells in producing IL-17 
in the infected liver in producing IL-17 late on in the immune response at a time point coinciding 
with the accumulation of high numbers of eggs in the liver. T regulatory cells were relatively highly 
engaged at the early phase of the infection and were probably induced by the parasite to suppress 
the disadvantageous Th1 immune response that could potentially clear the infection. Hence, down 
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regulating the T regulatory response at an early phase of infection may help the host clear the 
infection even though this may also contribute to host injury by the generation of a pro-
inflammatory Th1 immune response. Generally, the Th2 immune response observed in the present 
study, which was predominant at the later phase of the infection, seems more of a Type II 
inflammatory type rather than a Type II regulatory response [251] as the former is more common in 
allergic and fibrotic reactions of the type evident in CBA mice which produce a severe form of 
schistosome-induced fibrosis. We also speculate that anti-schistosome vaccine candidates that can 
primarily induce a pronounced Th1 immune response before the parasite commences egg-laying 
would result in parasite clearance and that enhanced host resistance to schistosomiasis might be 
feasible. 
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Chapter 3 
Recombinant  ligand binding domain of the S. japonicum insulin receptor 
(rSjLD1) 
3.1. Introduction 
 
Parasites have evolved specific receptors to exploit biological molecules of their hosts enabling 
them to better adapt to the host environment. One important example is the insulin receptor which 
enables schistosomes and other parasites to utilize host insulin which has a major effect on their 
carbohydrate and lipid metabolism [230, 269-273]. A previous study showed 1,101 genes of adult 
worms of S. japonicum were up-or down-regulated when they were exposed to insulin [274]. Then, 
it was demonstrated that S. japonicum encodes mammalian like insulin receptors indicating host 
hormones such as insulin might facilitate the development and maturation of schistosomes [273]. 
 
The insulin receptor (IR) of schistosomes is able to bind with host insulin to regulate and control 
worm growth and development. A recent study revealed that S. japonicum has two discrete IRs 
(SjIR-1 and SjIR-2), that share high sequence identity with their S. mansoni homologues (SmIR-
1 and SmIR-2), and were shown to bind to human insulin [187]. Furthermore, RNA interference 
(RNAi) knock down of the SjIRs  produced their less expression combined with a lowering in the 
transcription level of downstream genes of the insulin pathway that are linked with glucose 
metabolism and schistosome fecundity [190]. Moreover, as insulin is essential for glucose uptake, 
the viability of schistosome larvae was increased when they were cultured with insulin in vitro 
[275].  
 
As a result, the L1 sub domains of the IRs of S. japonicum (Ligand binding domains) (SjLD1 and 
SjLD2) were considered to be potential schistosome vaccine targets. Recently, SjLD1 and SjLD2 
were tested as vaccine candidates in CBA mice and they were shown to generate high levels of IgG 
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antibodies, resulting in a reduction in faecal eggs, liver granuloma density and mature intestinal 
eggs, and the stunting of adult worms in vaccinated animals [188, 190].  
 
3.2. Expression of rSjLD1  
 
His-tagged rSjLD1 and rSjTPI proteins were expressed in the Escherichia coli expression system 
[276]. A cDNA fragments (1,065 bp)  and (714bp) encoding SjLD1 and SjTPI respectively were 
amplified by PCR followed by ligating into the pET28b vector (Invitrogen, Carlsbad, CA,USA). 
Recombinant plasmids (rSjLD1 and rSjTPI) were transformed into E. coli BL21 (DE3) cells 
(Invitrogen) for expression and purification. In brief, 10 μl of transformed bacteria were added to 10 
ml of Luria Bertani (LB) media with 10 μl of 30mg/ml Kanamycin (final concentration was 
30μg/ml)  into a 50 ml falcon tube. The culture was then incubated at 370C on a shaker at 220 rpm. 
The following day, it was transferred into 500 ml of LB with 500 μl of Kanamycin, incubated again 
at 37
0
C on the shaker for 4 hours and its optical density assessed; on  reaching a range of 0.4-1, 50 
μl of 1M isopropyl B-D- thiogalacto-pyranoside (IPTG) (final concentration of 0.1mM) were added 
in order to induce rSjLD1 protein production. The culture was then incubated again at 37
0
C for 4 
hours on the shaker at the same speed. Finally the bacteia were harvested by ultracentrifugation at 
2,975×g for 15 minutes at 4
0
C and resuspended with 20 ml of bacterial pellet lysis buffer (500mM 
Tris-Hcl, 25% sucrose, 10mM imidazole). 
 
 
3.3. rSjLD1 protein extraction 
 
The bacteria were first digested with 125 μg/ml of freshly prepared lysozyme, 10 μg/ml of DNase, 
and 100mM of protease inhibitor (Phenylmethane sulfonyl fluoride (PMSF)) was added to block 
excess DNA and interfering protease.Then, the bacterial cells were subjected to sonication for 4-6 
minutes on ice (less than 20 outputs). The sonicated samples were transferred to small sterile ultra 
centrifuge tubes and centrifuged at 12,000×g for 15 min at 4 
0
C. The pellets were then washed twice 
with bacterial pellet wash buffer and resuspended with 20ml LD1 resolubilizing buffer. For an 
optimum  result the resuspended pellet was left overnight at 4
0
C on a wheel shaker. The 
resolubilized protein were centrifuged at 12,000×g for 30 min at 4
0
C to remove any remaining 
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insoluble material and filtered through a 0.22μm bottle filter (MERCK,Millipore, Australia,   
SCGVT05RE | Steritop Threaded Bottle Top Filter). 
 
3.4. SjLD1 purification 
 
Ni-NTA agarose (Qiagen, Hilden, Germany) columns were used to purify the rSjLD1 protein. The 
Ni-NTA resin was inverted gently to mix and 4ml of slurry were transferred to the top of the 
column, allowing the resin to pack by gravity resulting in approximately 2ml of packed resin. To 
equilibrate the column, 6 ml of sterile de-ionized water first and then 10 ml GMCAC-0 and finally 
6ml GMCAC-10 were added sequentially. The rSjLD1 protein was then loaded (20ml) onto the NI-
NTA resin, the column was washed with 6 ml of GMCAC-0 until no unbound protein was detected 
in the flow through. The Bradford reagent was  used (100μl of 1:5 diluted reagent mixed with 20μl 
of flow through) to check for the presence of protein. A complete disapperance of blue color 
indicated the absence of any protein. Then, the column was washed with 30 ml of GMCAC-20 or 
until no unbound protein was detected in the flow through (as described above). Finally, the protein 
was eluted with GMCAC-250 and the first 15ml of flow through were collected. In order to confirm 
the presence of  the purified rSjLD1, SDS-PAGE was performed and a protein of the expected 
molecular weight (44KD) was obsereved. 
 
3.5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Nine μl of the rSjLD1protein sample were mixed with 3 μl of 4x loading buffer and heated at 1000C 
for 10 minutes. First 3.5 μl of loading protein marker were added  into the first lane of a Mini-
protein gel (Bio- Rad Gladesville, Australia,) and different concentrations (1mg/ml, 0.5 mg/ml, 0.25 
mg/ml, 0.125 mg/ml, 0.0625 mg/ml, 0.03125 mg/ml, 0.0156 mg/ml) of bovine serum albumin 
(BSA) protein were loaded into the other seven lanes to determine the concentration of rSjLD1. 
Finally 10 μl  rSjLD1 protein sample were loaded, the appropriate voltage (120V) was set and the  
electrophoresis was run for 50 minutes. 
 
The SDS-PAGE gel was then moved to a container, covered with Coomassie Blue stain, 
microwaved for 30 seconds, and incubated with the stain for 10 minutes on a rocking table. The 
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Coomassie stain was poured off and the gel rinsed in water to remove residual stain. Finally fresh 
Destain solution was added into the container containing the gel. Then, the gel was examined for 
the presence of  the rSjLD1 protein band, and the  thickness and size of the rSjLD1 protein band 
was compared with the BSA bands in order to estimate the concentration of  the rSjLD1 protein 
(Figure 3.1). 
 
 
      
        
Figure 3.1. Confirming the integrity and molecular size of the purified rSjLD1. Following 
purification of rSjLD1 by Ni-NTA agarose (Qiagen, Germany) column, the presence and purity of 
the recombinant protein were confirmed by SDS-PAGE. The arrow indicates the position and the 
size of the rSjLD1 protein. 
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3.6. Dialysis of  the rSjLD1 protein  
 
The purified rSjLD1, were diluted 1:2 (15 ml of sample diluted with 30 ml of dialysis buffer) with 
dialysis buffer, was transfered into a small section of SnakeSkin Dialysis Tubing (Thermo 
Scientific, Rockford, USA) that was first activated with Milli-Q water (Millipore Carlsbad,CA, 
USA). The dialysis tube containing the protein was placed in 2L of dialysis buffer made with 3M 
Urea and incubated at 4
0
C.  Every three hours the dialysis buffer was replaced by a buffer with a 
lower concenentrion of urea (3M, 2M, 1M and then 0M). Because there was aggregation of the 
protein, a significant amount of rSjLD1 pellet was produced. Pellet formation commenced when the 
recombinant protein was in 1M Urea, resulting in significant loss of soluble rSjLD1. However, in 
order to minimize the loss, optimization was undertaken by lowering the inducer (IPTG) 
concentration. Moreover, by reducing the PH of the refolding buffer from pH 7.0 to pH 4.5, so it 
was far from the iso-electric point of the rSjLD1 protein (7.4), it was possible to obtain a 
significantly higher amount of soluble rSjLD1 protein. After completing the dialysis process, the 
protein sample were centrifuged at 5,200×g at 4
0
C to pellet the insoluble material and the 
supernatant was collected. 
 
3.7. Concentrating SjLD1 
 
Concentrating the soluble rSjLD1 were performed using 30KDa Amicon Ultra Centrifugal Filter 
Units. The protein sample was loaded on to the top of the filter and was gradually concentrated (to 
the lowest possible volume; 3-5ml) in steps centrifuging each time at 4000×g at 4
0
C for 20 minutes, 
resuspending the remaining volume at the top of the filter each time, and discarding the flow 
through. The concentration was done to lowest possibel volume (3-5ml). 
 
3.8. Removal of lipopolysacharides (LPS) from the purified and concentrated rSjLD1 
 
Lipopolysaccharides (LPS), major components of the gram negative bacterial cell wall, are common 
contaminants in plasmid DNA preparations and recombinant proteins and also they induces very 
large immune responses necessitating their removal from protein samples. Before LPS removal, the 
                                                                                                                                                                                                                                       
80 
                                                                                                                                                                                                                                                     
protein sample, in 8% sucrose, was diluted with sucrose-free buffer (300mM Nacl, 50mM 
NaH2PO4, PH 4.5) to reduce the sucrose concentration to 6% as the higher sucrose concentration 
interfered with LPS removal. Then, 1% Triton X-114 was added to the purified and dialysed 
rSjLD1 protein and the  sample placed on a wheel shaker and incubated at 4
0
C for 30 minutes. 
Then, the sample was transferred to a water bath, incubated at 37
0
C for 10 minutes then centrifuged 
at 20,000×g in 1.5ml eppendorf tubes at room temperature for 10 minutes. Finally, the upper 
aqueous phase containing the LPS free-rSjLD1 protein was carefully collected. 
 
3.9. Determining  concentration of  rSjLD1 and rSjTPI 
After the rSjLD1 had been concentrated and the LPS removed, the concentration of the protein was 
estimated. As mentioned above, the band thickness of the rSjLD1 and rSjTPI protein band were 
compared with bands of the different concentrations of BSA protein for estimating their 
concentration (Figure 3.2) . 
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Figure 3.2. Determining the concentration of soluble rSjLD1 and rSjTPI. The concentrations of 
the solubilized recombinant proteins were determined by SDS page by comparison with the  bands 
of  known concentrations of  the BSA protein. 
 
3.10. Endotoxin testing of purified rSjLD1 
 
The complete removal of LPS was confirmed by using a Pierce LAL Chromogenic Endotoxin 
Quantitation Kit ( Thermo Scientific, Rockford, USA). Briefly, a microplate was pre-equilibrated in 
a heating block for 10 minutes at 37
0
C and 50 μl of unknown sample replicate and a standard with 
different known concentrations of endotoxin was added. Then, 50 μl Limulus Amebocyte Lysate 
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(LAL), a proenzyme activated by endotoxin (if any present), was added and the sample incubated at 
37
0
C for 10 minutes.  Chromogenic Substrate solution (100 μl) was then added and the sample 
incubated at 37
0
C for 6 minutes followed by the addition of  100 μl Stop Reagent (25% acetic acid). 
Then the absorbance was measured at 405 nm on a plate reader. 
 
3.11. Production of  insoluble rSjLD1 for vaccination 
 3.11.1. Insoluble rSjLD1 production 
A similar procedure was used to that described for the purification of rSjLD1 with minor 
modifications. In the dialysis step the protein sample was dialyzed with 1×PBS for 36 hours, 
changing the PBS twice a day. The dialyzed rSjLD1 pellet in PBS was transferred into a 50ml 
falcon tube and centrifuged at 4750 rpm at 4
0
C for 15 minutes. The supernatant was discarded and 
the pellet resuspended with 8ml PBS and vortexed for 1 minute to ensure complete mixing.  
 
3.11.2. LPS removal from the insoluble SjLD1 protein 
One percent Triton X-114 (80μl) was added into the 8ml protein sample and rigorously vortexed for 
at least 1 minute and incubated on ice for 5 minutes. Then it was subsequently vortexed again and 
incubated at 56
0
C for 1 minute.  Finally, it was transferred into eppendorf tubes that were pre-
weighted followed by centrifugation at 16,200g at room temperature for 7 seconds. Finally the 
upper phase containing the PBS and Triton ×-114 (leaving the pellet) was removed and the LPS 
free-rSjLD1 pellet were washed twice by adding 1 ml of sterilized PBS and centrifuging at 15,000g 
for 1 minutes at 4
0
C. The supernatant was finally discarded and the tubes containing the rSjLD1 
pellet were weighted.  
 
3.11.3. Estimating the perentage of the dry weight of rSjLD1 
The weight of rSjLD1 pellet (wet weight) was estimated by subtracting the weight of empty tubes 
from the weight of the tubes with the rSjLD1 pellet. However, since the rSjLD1 pellet contains 
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fluids in it, the actual weight (dry weight) of rSjLD1 protein  and its percentage (proportion) out of 
the weight rSjLD1 pellet (wet weight) was needed to be estimated. Hence, five rSjLD1 pellet 
contaminating tubes were already prepared and from these one having a wet weight of 32mg was 
randomly taken and 500μl of 1% SDS/PBS added to solubilise the protein.  From this 10 μl was 
used to run SDS PAGE to estimate the dry weight of the rSjLD1 and  4mg/ml of was obtained. The 
thickness and length of the band of rSjLD1 in the SDS PAGE was compared with different bands of 
the different concentrations of  BSA as discribed above to estimate the dry weight of the rSjLD1.  
 
In order to estimate the percentage of the dry weight out  of  the wight of of the rSjLD1 pellet (wet 
weight), the following calculation was used.  
 
 
Note: The numinator is the dry weight estimated using the SDS PAGE as described above and the 
denominator (64mg/ml ) is wet weight as a tube containing 32 mg wet weight of rSjLD1 pellet was 
dissolved in 500μ (0.5ml) of  1%SDS/PBS. 
Therefore, using the percentage the dry weight of the rSjLD1 pellet (6.25%), the dry weight (actual 
weight) of the other four different tubes containing the rSjLD1 pellet was estimated and used in 
calculation of  how much protein rSjLD1 pellet to be used for vaccination of mice. For example, if 
0.5mg of rSjLD1 (the actual dry weight) is required for vaccination (based on standard protocol) of 
mice, it was possible to know how much weight of rSjLD1 pellet (wet weight) should be used for 
the vaccination using the above formula as follows: 
      Wet weight = Dry weight/Percentage of dry weight 
                             0.5mg/6.25% =8mg 
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Therefore, the tube containing rSjLD1 pellet with wet weight of 8mg was used to prepare for the 
vaccination. 
 
3.11.4. Preparation of rSjTPI for vaccination of CBA mice 
rSjTPI was used from the stock stored at -80
0
C in the Molecular Parasitology Laboratory of 
Queensland Institute of Medical Research Institute (QIMR Berghofer). A brief summary on 
expression, purification and removal of LPS is as follows: 
His-tagged rSjTPI proteins were expressed in the Escherichia coli expression system [277]. A 
cDNA fragment of cDNA fragment (714bp) encoding the SjTPI, were amplified by PCR and 
ligated into the pET28b vector (Invitrogen, Carlsbad, CA, USA). Recombinant plasmids (rSjTPI) 
were transformed into E.coli BL21 (DE3) cells (Invitrogen) for expression.  Following the digestion 
and sonication of the bacterial cell pellet and centrifugation, the supernatant containing the soluble 
rSjTPI were taken (pellet used in case of rSjLD1 as it is insoluble protein) for purification. 
Purification of the rSjTPI was performed using Ni-NTA affinity chromatography. Triton X-114 was 
used to remove LPS similar to rSjLD1. 
 
3.11.5. Vaccination of CBA mice with rSjTPI-LD1 
CBA mice were subcutaneously injected with the antigen mix (rSjTPI-LD1) comprising 
recombinant triose phosphate isomerase (rSjTPI) and the ligand binding domain (LD1) of 
recombinant insulin receptor (rSjLD1) formulated with Montanide ISA 720VG. 
 
Each CBA mouse was injected with 25μg of rSjTPI-LD1 insoluble rSjLD1 (comprising 12.5 μg 
insoluble rSjLD1 and 12.5 μg soluble rSjTPI). In each of the trials, 25 CBA mice were vaccinated 
with rSjTPI-LD1 but to ensure sufficient protein was available, the amount of protein needed was 
calculated for 40 mice.  The volume of the antigen mix injected per mouse was 50 μl comprising; 
35 μl of Montanide ISA 720 VG (adjuvant) and 15 μl of the rSjTPI-LD1 (1400 μl of the adjuvant 
with 600 μl of the rSjTPI-LD1 was prepared for 40 mice).  
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The T cell immune response in naïve CBA mice immunized with the rSjTPI-LD1 vaccine in two 
independent trials is described in Chapter 4. The vaccine efficacy and T cell immune responses in 
CBA mice immunized with the rSjTPI-LD1 vaccine and challenged with S. japonicum cercariae are 
described in Chapter 5.                                
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Chapter  4 
T cell immune responses in naïve CBA mice immunized with the multi- valent 
rSjTPI-LD1 vaccine 
4.1. Introduction 
 
Schistosomiasis is a chronic water-borne parasitic disease endemic in 72 countries with at least 252 
million cases worldwide (Chapter 1)  [277]. It has recently been shown to have emerged in Europe 
with patients in France, Germany and Italy identified with the disease originating on the French 
island of Corsica [278]. The main strategy to prevent and control schistosomiasis has focused on 
mass drug administration (MDA) using praziquantel (PZQ) [23]. However, this strategy cannot 
prevent reinfection and PZQ does not kill migrating larvae which necessitates the development of 
other interventions such as vaccination as part of an integrated approach to the control and 
elimination of  schistosomiasis [34]. 
 
As discussed in detail in Chapter 1, there are many anti-schistosme vaccine candidates that are at 
different stages of development. Among them, rSjLD1 and rSjTPI are the focus of this study. 
Increased knowledge of the immune response against schistosomiasis is pivotal to understanding 
which immune components are involved in making the host resistant to schistosomiais so that an 
effective anti-schistosome vaccine can be developed. Similarly, studying the immune response 
induced after vaccinationis is also very important because it can provide insight on modulating the 
immune response in order to develop a more efficacious vaccine. Such an approach would also rule 
out whether vaccine efficacy data from vaccinated/challenged mice are indeed real as it has been 
suggested that the murine vaccine/challenge model for schistosomiasis may be flawed [48].  
 
At the present time there is, surprisingly, limited available data on the effects of any vaccine 
candidate on the T cell immune response in schistosomiasis although T cell immunity has been 
shown to be an important component of the immune response to the schistosome parasites. Our 
laboratory has targeted the ligand binding domain (SjLD1) of the insulin receptors (SjIRs) and 
triose-phosphate isomerase (rSjTPI) as putative vaccine candidates against schistosomiasis 
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japonica. An antigen mixture comprising a combination of rSjTPI and rSjLD1 (rSjTPI-LD1) was 
tested to determine its effect on the T cell immune response in naive CBA mice (Figure 4.1.). 
 
4.2. Materials and Methods 
4.2.1. Immunization of mice 
Fifty CBA mice were randomly grouped into two groups. The first group of 25 mice were 
subcutaneously injected with 25μg rSjTPI-LD1 - formulated with Montanide ISA 720VG - at a 
ratio of 30:70, on days 0 and then boosted on day, 15 and day 30.  A control group of twenty five 
mice was injected with PBS and Montanide ISA 720VG using the same immunization protocol.  
 
4.2.2. Culling of mice 
Five mice from each group were culled at different time points (at weeks 2 ,5, 6, 7 and 8 post- 
second booster last vaccination) in order to collect spleen and liver samples and to evaluate the 
immune response at each of the time points  (Figure 4.1).   
 
 
 
 
Figure 4.1. Different time points when the immune response was determined after naïve CBA 
mice were vaccinated with rSjTPI-LD1. Five mice from each group (vaccinated animals and 
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adjuvant controls) were sacrified at weeks 2, 5, 6, 7 and 8 post the second booster with vaccine or 
adjuvant only, and spleens and livers were removed. One day before each time point blood was 
collected to prepare serum and determine the levels of IgG antibody generated. 
 
4.2.2. Blood collection 
Fifty μl of blood from the CBA mice at weeks 2, 5, 6, 7 and 8 post-second boost were collected, one 
day prior to the culling of the mice. The blood collection and processing were carried out as 
described (Chapter 2, section 2.2.3). 
 
4.2.3. Preparation of ligand binding domain (SjLD1) of the insulin receptor (SjIR) and triose-
phosphate isomerase (rSjTPI) 
The preparations of rSjLD1 and rSjTPI were carried out as described (Chapter 3) 
 
4.2.4. Lipopolysaccharide (LPS) removal from rSjLD1 and rSjTPI and endotoxin test 
LPS removal and endotoxin testing were undertaken as described (Chapter 3).  
 
4.2.5. Measurement of anti-rSjLD1 and rSjTPI antibodies 
100 μl of 1μg/ml of rSjLD1and rSjTPI in coating buffer (Bicarbonate buffer, pH 9.6) were coated 
separately on immunoplates (NUNC, Denmark) at 4
0
C overnight. The plates were blocked with 5% 
(v/v) skim milk in PBS for an hour at 37
0
C followed by 3 times washing with PBS containing 
0.05% (v/v) Tween 20 (PBST). Mouse serum samples were serially diluted (1:200 -1:204,800) with 
5% skim milk in PBST (100μl/well) and incubated at 370C for 2 hours. Sheep anti mouse IgG 
antibody conjugated with peroxidise (diluted 1: 20, 000) was used as secondary antibody and 
incubated for 1 hour at 37
0
C.  PBST washes were applied five times after each step, 2 min between 
each wash. Finally, reactions were developed using 100 μl/well of substrate (3, 3, 5, 5-
tetramethylbenzidine solution (TMB) (Aldrich, Switzerland)) for 10 minutes and stopped using 2M 
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sulphuric acid (50 μl/well). A microplate reader was used to read optical density (OD) at 450nm 
from all serum samples that were run in duplicate. A positive test result was defined when the OD 
values was greater than two times the mean of OD value obtained with serum samples from control 
mice. 
 
4.2.6. Cell culture of spleen and liver cells 
Cells from spleen and liver was isolated as described (Chapter 2) 
  
4.2.7. Cell culture conditions  
The cells were stimulated separately with 10μg/ml rSjLD1, rSjTPI, SEA and SWAP and 0.5 μg/ml 
Con A as a positive control and medium only was added to cells plated as a negative control. After 
68 hours of cell culture, Brefeldin A (BFA) was added to the plates at a final concentration of 200 
µg/ml. Cells were harvested 4 hours after the addition of BFA. 
4.2.8. Flow cytometry  
Assessment of T effector and T regulatory immune responses was carried out as described 
(Chapter 2). 
 
4.2.9. Statistical Analysis 
Statistical analysis was carried out as described (Chapter 2). 
4.3. Results 
4.3.1. Antibody response to rSjLD1 and rSjTPI 
High levels of both anti rSjTPI and rSjLD1 IgG antibodies were detected by ELISA. The IgG 
response against both proteins peaked at week 6 post the last booster vaccination but dropped 
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thereafter (Figure 4.2). Anti-sera at the peak time point demonstrated a titre of 1; 102,400 for 
rSjTPI and 1:204,800 for rSjLD1 (Table 4.1). 
 
 
 
Figure 4.2. Kinetics of specific anti–rSjTPI and anti-rSjLD1 IgG antibodies determined by 
ELISA in sera from rSjTPI -LD1 vaccinated CBA mice at different time points post-
vaccination and from control mice given adjuvant only. The results are presented as mean 
absorbance +SEM measured at 450nm. Statistically significant differences between rSjTPI or 
rSjLD1 and adjuvant (ISA 720 VG) immunized groups are denoted by asterisks (*=p value ≤ 0.05, 
**=p value ≤0.001). 
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Table 4. 2. Antibody endpoint titres of anti-rSjTPI and anti-rSjLD1 antibodies of CBA mice 
vaccinated with rSjTPI-LD1 
 
 
 
4.3.2. Effect of rSjTPI -LD1 on the T cell mediated immune response 
4.3.2. 1. T effector immune response in rSjTPI -LD1 vaccinated mice and controls. 
4.3.2.1.1. Th1 immune response 
At two weeks post the last booster vaccination, the proportion of IFN-γ-producing γδ T cells was 
higher among the vaccinated group than the control group following rSjTPI and SWAP re-
stimulation (Figure 4.3.E).  Moreover, a significantly higher percentage of IFN-γ producing CD8+ 
splenocytes was observed in the vaccinated group when re-stimulated with rSjTPI (Figure 4.3.B). 
The number of liver lymphocytes obtained was not sufficient to be cultured necessitating pooling of 
mouse samples from each group; as a result, statistical analysis was not possible. Re-stimulated 
Weeks after last booster 
vaccination 
Titres 
Anti  rSjTPI Anti  rSjLD1 
 
2 
 
1:51, 200 
 
1:12, 800 
 
5 
 
1:102,400 
 
1:204, 800 
 
6 
 
1:102,400 
 
1:204, 800 
 
7 
 
1:25,600 
 
1:25, 600 
 
8 
 
1:25, 600 
 
1:25, 600 
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with rSjLD1, relatively higher proportion of IFN-γ producing liver CD4+ T cells was demonstrated 
among the vaccinated group compared with the controls. (Figure 4.3.D)  
 
At week five post the last booster vaccination, the vaccinated mice demonstrated significantly 
higher percentage of IFN-γ-producing spleen γδ T cells that were re-stimulated with SWAP (Figure 
4.4.C). However, at week 6 post the last booster vaccination and thereafter, there was no significant 
difference in the proportion of cells producing IFN-γ (Th1 immune response) among the vaccinated 
and unvaccinated groups (Figure 4.5 and Figure 4.6). 
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Figure 4.3. Frequency of IFN-γ-producing cells in CBA mice at two weeks post the last 
booster vaccination with rSjTPI-LD1 and following stimulation with rSjTPI, rSjLD1, SEA, 
SWAP or medium only in vitro. Splenocytes and liver lymphocytes were restimulated and co-
cultured with rSjTPI, rSjLD1, SEA, SWAP or medium only different for 72 hours. (A) Interferon 
gamma-producing CD4
+
 splenocytes of vaccinated, unvaccinated (only adjuvant and PBS 
administered) and naive CBA mice.  (B) Interferon gamma-producing CD8
+
 splenocytes of 
vaccinated, unvaccinated (only adjuvant and PBS administered) and naive CBA mice. (C) 
Interferon gamma-producing liver CD4
+
 T cells of vaccinated, unvaccinated (only adjuvant and 
PBS administered) and naive CBA mice.   (D) Interferon gamma-producing liver CD8
+
 T cells of 
vaccinated, unvaccinated (only adjuvant and PBS administered) and naive CBA mice.  Note, in C 
and D, a pooled sample was taken from five mice per group as there were insufficient liver 
lymphocytes to perform the cell culture on individual samples. (E) Interferon gamma-producing 
spleen gamma delta T cells of vaccinated, unvaccinated (only adjuvant and PBS administered) and 
naive CBA mice. Statistically significant differences between the groups are denoted by asterisks 
(*=p value ≤ 0.05, **=p value ≤0.001). 
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Figure 4.4. Frequency of IFN-γ producing cells in CBA mice at five weeks post the last 
vaccination with rSjTPI-LD1 and following stimulation with rSjTPI, rSjLD1, SEA, SWAP or 
medium only in vitro. Splenocytes and liver lymphocytes were restimulated and co-cultured with 
the different antigens for 72 hours. (A) Interferon gamma producing CD4
+
 splenocytes of 
vaccinated and unvaccinated CBA mice.  (B) Interferon gamma-producing CD8
+
 splenocytes of 
vaccinated and unvaccinated CBA mice.  (C) Interferon gamma- producing spleen γδ T cells from 
vaccinated and unvaccinated CBA mice.  Statistically significant differences between the groups are 
denoted by asterisks (*=p value ≤ 0.05, **=p value ≤0.001). 
 
 
 
Figure 4.5. Frequency of IFN-γ producing cells in CBA mice at six week post the last booster 
vaccination with rSjTPI-LD1 and following stimulation with rSjTPI, rSjLD1, SEA, SWAP or 
medium only in vitro. Splenocytes were restimulated and co-cultured with the different antigens 
for 72 hours. (A) Interferon gamma-producing CD4
+
 splenocytes of vaccinated and unvaccinated 
CBA mice.  (B). Interferon gamma-producing CD8
+
 splenocytes of vaccinated and unvaccinated 
CBA mice.    
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Figure 4.6. Frequency of IFN-γ producing cells of CBA mice at eight weeks post the last 
booster vaccination with rSjTPI -LD1 and following stimulation with rSjTPI, rSjLD1, SEA, 
SWAP or medium only in vitro. Splenocytes and liver lymphocytes were restimulated and co-
cultured with the different antigens for 72 hours. (A) Interferon gamma-producing CD4
+
 
splenocytes of vaccinated, and unvaccinated CBA mice. (B) Interferon gamma- producing CD8
+
 
splenocytes of vaccinated and unvaccinated CBA mice. (C) Interferon gamma-producing CD4
+
 
liver lymphocytes. (D) Interferon gamma-producing CD8
+
 liver lymphocytes. For C and D, pooled 
sample were taken from five mice per group as there were insufficient liver lymphocytes to perform 
the cell cultures on individual samples. 
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4.3.2.1.2. Th2 immune response 
At two weeks post the last booster vaccination, there was a significantly higher percentage of IL-4 
producing spleen γδ T cells among vaccinated mice compared with the controls upon re-stimulation 
with rSjTPI, SEA, SWAP and even without re-stimulation (cultured with medium only) (Figure 
4.7.C). Moreover, a significantly higher percentage of IL-4 producing CD8
+
 T cells was observed in 
the vaccinated mice when re-stimulated with rSjTPI, rSjLD1 and SWAP. (Figure 4.7.B). At week 5 
post the last booster vaccination, relatively higher percentage of IL-4 producing CD4
+
 spleen and 
liver lymphocytes were observed when they were  re-stimulated with rSjTPI and rSjLD1 (Figure 
4.8.A and Figure 4.8.C).  
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Figure 4.7. Frequency of IL-4 producing cells of CBA mice at two week post the last booster 
vaccination with rSjTPI-LD1 and following stimulation with rSjTPI, rSjLD1, SEA, SWAP or 
medium only different in vitro. Splenocytes and liver lymphocytes were restimulated and co-
cultured with the different antigens for 72 hours.  (A) IL-4-producing CD4
+
 splenocytes of naïve, 
vaccinated and unvaccinated CBA mice.  (B) IL-4-producing CD8+ splenocytes cells naïve, 
vaccinated and unvaccinated CBA mice. (C) IL-4-producing spleen γδ T cells of vaccinated and 
unvaccinated CBA mice.   (D) IL-4-producing CD4+ liver lymphocytes of vaccinated and 
unvaccinated CBA mice. Statistically significant differences between the groups are denoted by 
asterisks (*=p value ≤ 0.05, **=p value ≤0.001). 
 
  
 
Figure 4.8. Frequency of IL-4 producing cells of CBA mice at five week post the last booster 
vaccination with rSjTPI-LD1 and following stimulation with rSjTPI, rSjLD1, SEA, SWAP or 
medium only in vitro. Splenocytes and liver lymphocytes were restimulated and co-cultured with 
different the antigens for 72 hours. (A) IL-4-producing CD4
+
 splenocytes of vaccinated and 
unvaccinated CBA mice.  (B) IL-4-producing CD8
+
 splenocytes of vaccinated and unvaccinated 
CBA mice   (C) IL-4-producing CD4
+
 liver of vaccinated and unvaccinated CBA mice. Statistically 
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significant differences between the groups are denoted by asterisks (*=p value ≤ 0.05, **=p value 
≤0.001). 
 
4.3.2.1.3. T regulatory immune response in rSjTPI-LD1-vaccinated and control mice. 
At 8 weeks post the last booster vaccination, there was a significantly higher percentage of Tregs 
evident in the vaccinated group compared with the controls but only when re-stimulated with 
rSjLD1 (Figure 4.9). 
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Figure 4.9. Frequency of Tregs in CBA mice at eight weeks posts the last booster vaccination 
with rSjTPI–LD1 and following stimulation with rSjTPI, rSjLD1, SEA, SWAP or medium 
only in vitro.  (A-B) Representative staining showing CD25
+ 
Foxp3
+
 splenocytes in CBA mice. (A) 
Mice administered Montanide ISA 720 VG adjuvant only but restimulated with rSjLD1 in vitro (B) 
Mice that were vaccinated with rSjTPI-LD1 and restimulated with rSjLD1. (C) Bar graphs showing 
the frequency of Tregs in vaccinated and unvaccinated mice after the splenocytes were restimulated 
with rSjTPI, rSjLD1, SEA, SWAP or medium only. Statistically significant differences between the 
groups are denoted by asterisks (*=p value ≤ 0.05, **=p value ≤0.001). 
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4.4. Discussion 
 
A recent report [280] has suggested that undertaking anti-schistosome vaccine trials in mice may be 
problematic and may generate spurious protective data. The report questioned whether such trials in 
mice are able to effectively determine whether any significant worm reduction data obtained are due 
to acquired immunity induced by a candidate vaccine or are rather due to mouse vasculature  
physiology that impacts on schistosome worm survival [279]. Therefore, evaluating whether any 
schistosome vaccine candidate can induce a true protective immune response or not is critical. In 
this chapter, an antigen mix, comprising recombinant rSjTPI and rSjLD1 (rSjTPI-LD1) was tested 
to examine its effect on the antibody and T cell immune response in naive CBA mice at different 
time points without subjecting the mice to cercarial challenge. 
 
 
Vaccination with rSjTPI-LD1 induced a significantly high level of both anti-rSjTPI and anti-
rSjLD1-specific IgG antibodies at all time points post-vaccination compared with controls (Figure 
4.1). This is a feature common to other schistosome vaccine candidates tested in mice [280, 281]; 
moreover, another study showed that IgG antibodies are important for the protection against 
schistosomes [282]. Here, the anti-rSjTPI and anti-rSjLD1 IgG antibody response peaked at week 6 
after the last booster vaccination with the highest titers of 1:102,400 and1: 204,800 obtained, 
respectively (Figure 4.2). In most schistosome vaccine studies utilising the mouse model, animals 
are generally subjected to cercarial challenge at week 2 post the last vaccination boost. We 
determined the antibody response at this time point and subsequently, but without parasite 
challenge, and found significantly high levels of specific IgG antibodies up to week 8 post the last 
booster vaccination. Therefore, improved protection may occur if the time of cercarial challenge is 
delayed to several weeks beyond the normal week 2 post the last booster vaccination.  
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            The T cell-mediated immune response in mice was also monitored following vaccination with 
rSjTPI-LD1 at different time points. At week 2 post the last vaccination booster ( at the time just 
prior to challenge), there was no difference in the Th1 immune response induced by CD4
+
 T cells in 
the rSjTPI-LD1 vaccinated and control groups. However, the Th1 immune response shown by 
spleen CD8
+
 and γδ T cells was significantly higher in the vaccinated mice than the controls when 
the cells were restimulated with rSjTPI and rSjLD1 respectively (Figure 4.3.B and 4.3.E). A 
similar Th1 immune response (IFN-γ-producing cells) by γδ T cells has also been observed in pigs 
vaccinated with Mycobacterium bovis where these cells play an important role in the protective 
immune response [283]. Again, similar to the results described here, several studies conducted on 
tuberculosis demonstrated a protective immune response by γδ T cells at the early phase of infection 
[284-286].  At week 5 post the final booster vaccination, mice receiving rSjTPI-LD1 showed a 
significantly higher percentage of IFN-γ producing γδ T cells when restimulated with the worm-
derived antigen (SWAP) (Figure 4.4.C). On the other hand, the Th1 immune response (IFN-γ 
produced) by CD4
+
 and CD8
+
 T cells was similar among the vaccinated and the control groups 
(Figure 4.4.A and Figure 4.4.B). This could be due to the ability of γδ T cells to negatively 
regulate the proliferative capacity of CD4
+
 and CD8
+ 
T cells [286]. Moreover, the Th2 immune 
response (IL-4 producing cells) was significantly higher at weeks 2 and relatively higher (but not 
significantly) at week 5 post the final booster vaccination in the vaccinated group. ). Similar to the 
Th1 immune response, significantly higher percentage of IL-4 producing γδ T cells was observed in 
the vaccinated group when they were restimulated with rSjTPI, SWAP and even in medium only 
(Figure 4.7.C). Since we used pooled liver samples, we were unable to determine whether the 
difference was statistically significant in liver lymphocytes but the percentage of liver CD4
+ 
T cells
 
 
producing IL-4 (characterising a Th2 immune response) was relatively higher when the vaccinated 
group were restimulated with rSjLD1 and rSjTPI (Figure 4.7.D and Figure 4.8.C) 
 
The immune response generated by γδ T cells, the induction of Treg by rSjLD1 and unknown 
factors may suppress both the Th1 and Th2 immune responses that are expected mainly to be 
mounted by CD4
+
 cells although the precise mechanism involved requires further investigation. 
However, the Th1-based immunity mediated by the γδ T cells induced by the vaccine may provide 
the protective effect required. 
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Overall, the findings in this Chapter show that the rSjTPI-LD1 vaccine induced both humoral and 
cell mediated immunity at a time relatively soon after vaccination (around week 5 post the final 
booster vaccination); IFN-γ and IL-4 producing γδ T cells and  CD8+ T cells were the major cells 
induced by the rSjTPI-LD1 vaccine. However, the Th1 and Th2 immune response mediated by 
CD4
+
 appeared to be suppressed thereby potentially limiting the ability of this vaccine candidate to 
mount a solid protective immune response. 
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Chapter   5 
Vaccine efficacy and T cell immune responses in CBA mice immunized with  the 
rSjTPI -LD1 vaccine  and challenged with S. japonicum cercariae 
 
5.1. Introduction 
 
Determining the precise mechanism induced by a vaccine candidate that contributes to 
immunological protection is a critical step in vaccine design. Several studies have attempted to 
explore the nature of the T cell immune response generated following vaccination with anti-
schistosome vaccine candidates. For example, early studies showed that radiation-attenuated S. 
japonicum cercariae induced a polarized Th1 immune response reflected by a high level of IFN-γ 
production [287, 288]. In support, recent data obtained with several vaccine candidates against both 
S. mansoni and S. japonicum showed that the protective efficacy generated was again mainly due to 
the induction of a polarized Th1 immune response (shown by IFN-γ production) [289-292]. 
However, it has been are argued that a successful anti-schistosome vaccine will require the 
induction of both Th1 and Th2 cytokines rather than a highly polarized immune response [46, 293]. 
However, the design of a vaccine that can induce both Th1 and Th2 immune simultaneously is 
challenging.  
 
On the other hand, a parasite specific-IgE antibody and eosinophil-mediated immune response 
results in parasite killing in Schistosoma-infected humans and Th2 type cell mediated immunity has 
been shown to result in an acquired resistance to human schistosomiasis in human individuals [4, 
294, 295]. 
 
The majority of previous studies focusing on the protective immune mechanisms induced by anti-
schistosome vaccines explored only the involvement of Th1 and Th2 immune responses. However, 
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some recent studies indicate the possible participation of other T helper cells, notably Th17 cells. 
Whereas IL-17-mediated immune protection against other pathogens is well documented, there is 
limited data available in regards to schistosomiasis, particularly information involving vaccine-
induced immune protection. Furthermore, data on the involvement of regulatory T cells (Tregs) in 
vaccine-induced protection is limited.  
 
In Chapter 4, the T cell and antibody responses induced by an antigen mix, SjTPI-LD1, in naïve 
CBA mice were described. In this chapter, the T effector response (Th1, Th2 and Th17) and the 
involvement of Tregs immune response were evaluated in S. japonicum-infected CBA mice 
following vaccination with rSjTPI-LD1 (Figure 5.1.). 
 
 
5.2. Methods 
5.2.1. Immunization and challenge of mice 
Fifty CBA mice were randomly grouped into two groups. The first group of 25 mice were 
subcutaneously injected with 25μg of rSjTPI-LD1-formulated with Montanide ISA 720VG at a 
ratio of 30:70, on days 0, 15 and 30.  A control group of fifteen mice were injected with PBS and 
Montanide ISA 720VG using the same immunization protocol. The mice were boosted twice at 
intervals of two weeks. Two weeks after the last booster vaccination, the mice were challenged with 
34 cercariae of S. japonicum and the immune response at different time points determined (Figure 
5.1). 
 
5.2.2. Culling of mice 
Five mice from each group were sacrificed humanely at different time points (weeks 0, 3, 4, 5 and 6 
post cercarial-challenges) to determine worm and egg burdens and to collect spleen and liver 
samples to evaluate the immune response at each of the time points. 
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5.2.3. Blood collection 
 
Fifty μl of blood from the CBA mice at weeks 0, 3, 4, 5 and 6 weeks post cercarial challenge were 
collected (one day before culling the mice) to obtain serum as described (Chapter 2, section 2.2.3). 
 
 
 
Figure 5.1. Different time points when the immune response was determined after rSjTPI -
LD1 vaccinated CBA mice were challenged with S. japonicum cercariae. Five mice per group 
were sacrified at each time point and blood was taken one day before each time point to prepare 
serum for antibody measurements. 
 
 
5.2.4. Vaccine efficacy of rSjTPI -LD1 
Two independent vaccination-challenge trials in mice were undertaken. The total worm, paired 
worm numbers and liver egg numbers were determined to evaluate the protective efficacy of the 
rSjTPI-LD1 LD1vaccine. 
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5.2.4.1. Worm counts 
Adult S. japonicum worms were collected by perfusion from week 3 post-challenge and the total 
worm numbers and the number of worm pairs determined at week 3, 4, 5 and 6. Reductions in the 
total worm numbers and worm pair numbers were calculated as follows:  
 Percent reduction = ( the average number of total or paired worms in the unvaccinated mice the 
average number of total worms or paired worms in  the vaccinated mice)/  the average number of 
total or paired worms in  the unvaccinated mice X 100 [296]. 
 
5.2.4.2. Liver egg counts  
Liver egg counts were carried out as described (Chapter 2, section 2.2.5). A reduction in the 
number of liver eggs was calculated as follows: 
 Percent reduction = ( the average number of  liver eggs/gram of liver in unvaccinated mice- 
average number of liver egg/gram of liver in vaccinated mice)/ average number liver egg/gram of 
liver in  the unvaccinated mice X 100 [296]. 
 
5.2.5. Preparation of ligand binding domain (SjLD1) of the insulin receptors (rSjIRs) and 
triose-phosphate isomerase (rSjTPI) 
The preparation of rSjLD1 and rSjTPI was undertaken (Chapter 3) 
 
5.2.6. Lipopolysaccharide (LPS) removal from rSjLD1 and rSjTPI and endotoxin testing 
LPS removal and endotoxin testing was undertaken as described (Chapter 3).  
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5.2.7. Measurement of anti- rSjLD1and rSjTPI Antibodies 
Measurement of anti- rSjLD1and rSjTPI antibodies was undertaken as described (Chapter 4, 
section 4.2.5) 
5.2.8. Cell culture of spleen and liver cells 
Cells from spleens and livers were isolated as described (Chapter 2) 
  
5.2.9. Cell culture conditions  
Spleen and liver cell culture was carried out as described (Chapter 4, section 4.2.7). 
5.2.10. Flow cytometry 
Assessment of the T effector and T regulatory immune response was carried out as described 
(Chapter 2). 
5.2.11. Statistical Analysis 
Statistical analysis was carried out as described (Chapter 2) 
 
5.3. Results 
5.3.1. Vaccine trials 
5.3.1.1. Total worm burdens 
CBA mice were perfused at weeks 3, 4, 5 and 6 post- challenge infection with S. japonicum and 
worms were collected, counted and compared for the vaccinated and unvaccinated control animals 
in two independent vaccine trials. The trials resulted in small but significant average total worm 
reductions of 22.3% (P=0.0214) and 26.5% (P= 0.0265) in the rSjTPI-rSjLD1 vaccinated mice 
(Figure 5.1). 
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5.3.1.2. Worm pair burden 
There were also significant (P=0.045, P= 0.0281) worm pair reductions in the rSjTPI-rSjLD1 
vaccinated and challenged mice compared with the unvaccinated and infected controls in both the 
two independent trials (Figure 5.2). 
 
 
Figure 5.2. Total numbers of worms and paired worms per individual mouse compared for in 
the rSjTPI-LD1 vaccinated and challenged infected groups and the challenged infected 
control groups determined during the two independent vaccine trials. The total number of adult 
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worms and paired worms determined for vaccinated and infected controls were compared; *p< 0.05 
is significant.  
 
5.3.1.3. Liver egg burdens 
There was also significant liver egg reductions per gram of liver (41% and 54%) in the rSjTPI-
rSjLD1-vaccinated challenged mice compared with the unvaccinated infected controls in both trials 
(Figure 5.3). In trial 1, there was a liver egg reduction of 84.75% and 56.58% at weeks 5 and 6 post 
challenge infection, respectively, where as in trial 2, 58.67% and 52.87% of  liver egg reduction 
occurred at weeks 5 and 6 post challenge, respectively.  
 
 
 
 
Figure 5.3. Liver egg counts per gram of liver of CBA mice vaccinated with rSjTPI -LD1 and 
challenged with S. japonicum cercariae compared with unvaccinated but infected controls at 
two different time points. The number of eggs per gram of liver determined at different time 
points for vaccinated and infected controls was compared; *p< 0.05 is significant. 
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5.3.2. Number of splenocytes and liver lymphocytes  
Cells were isolated from the spleens and livers of vaccinated, unvaccinated (only adjuvant 
administered) and naive mice, and counted prior to culture. No data were collected on week 0 and 
week 3 post-challenge infection in trial 1.  There was no significant difference in the number of 
splenocytes among the naive, unvaccinated or vaccinated groups at week 0 (at the time of just prior 
to cercarial challenge) (Figure 5.4.A). Moreover, there was no significant difference in the number 
of splenocytes among unvaccinated and vaccinated mice in any of the different time points. The 
number of splenocytes peaked at week 3 post-challenge and declined after wards up to week 5 in 
both trials (Figure 5.5). 
 
There was no significant difference in the number of liver lymphocytes among the naive, 
unvaccinated or vaccinated groups at week 0 (at the time of just prior to cercarial challenge) (Figure 
5.4.B). Moreover, there was no significant difference in the number of liver lymphocytes between 
unvaccinated and vaccinated mice at the different time points. However, both independent trials 
showed there was a continuous and significantly increasing trend in the number of liver 
lymphocytes over the course of the infection (Figure 5.5). 
 
Figure 5.4. Number of splenocytes (A) and liver lymphocytes (B) in CBA mice at just prior to 
cercarial challenge. Both unvaccinated mice administered Montanide ISA720 VG (Adjuvant) and 
naive mice were used as controls. The figure shows the results obtained in trial 2. 
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Figure 5.5. Number of splenocytes in CBA mice vaccinated with rSjTPI-LD1 and challenged 
with S. japonicum cercariae. The number of splenocytes was determined at different time points 
post-cercarial challenge. The number of splenocytes in both the vaccinated and unvaccinated groups 
at week 0 (at the time of challenge) was compared with the number of splenocytes at the other time 
points post-challenge. Moreover, for all time points, the numbers of splenocytes between the two 
groups were compared but no significant differences were observed; *=p value ≤ 0.05, **=p value 
≤0.01 is significant. 
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5.3.3. Antibody response to rSjLD1 and rSjTPI 
The two independent trials showed that rSjTPI and rSjLD1 significantly induced specific IgG 
antibody responses in the vaccinated mice. The IgG response against both proteins peaked at week 
4 post-challenge followed by a decline up to week 6 post challenge. Moreover, the highest peak of 
the IgG response was at week 4 post challenge in both Trial 1 and 2 (Figure 5.6; Tables 5.1, 5.2).  
 
 
 
Figure 5.6. Kinetics of specific anti–rSjTPI and anti-rSjLD1 IgG antibodies determined by 
ELISA in the sera from rSjTPI-LD1 vaccinated and unvaccinated control CBA mice at 
different time points post-challenge in the two trials. Results are presented as mean absorbance + 
SEM measured at 450nm. Statistically significant differences between specific anti rSjTPI or anti 
rSjLD1 antibodies in the sera of vaccinated mice compared with sera from adjuvant (Montanide 
ISA 720 VG) only immunized animals are denoted by asterisks (*=p value ≤ 0.05, **=p value 
≤0.01). 
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Table 5.1. Antibody endpoint titres of anti rSjTPI and anti rSjLD1 IgG antibodies of CBA 
mice that were vaccinated with rSjTPI-LD1 and challenged with 34 S. japonicum cercariae 
(Trial 1). 
 
 
 
 
 
 
 
 
 
 
Weeks after 
challenge 
Titres 
Anti-rSjTPI Anti-rSjLD1 
 
4 
 
1:25,600 
 
1:204,800 
 
5 
 
1:25,600 
 
1:204,800 
 
6 
 
1:3,200 
 
1:12,800 
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Table 5.2. Antibody endpoint titres of anti rSjTPI and anti rSjLD1 IgG antibodies of CBA 
mice that were vaccinated with rSjTPI-LD1 and challenged with 34 S. japonicum cercariae 
(Trial 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.4. Effect of the rSjTPI -LD1 vaccine on  the T cell mediated immune response 
5.3.4.1. The T effector immune response in rSjTPI-LD1 vaccinated and S. japonicum- 
challenged CBA mice. 
The effects of rSjTPI-LD1 on the T effector (Th1, Th2 and Th17) immune response at different 
time points (week 0, 3, 4, 5 and 6) post cercarial challenge were determined in CBA mice. 
Weeks after 
challenge 
Titres 
Anti-rSj-TPI Anti-rSj-LD1 
 
0 
 
1:25,600 
 
1:204,800 
 
3 
 
1:25, 600 
 
1:204,000 
 
4 
 
1:51, 200 
 
1:204,800 
 
5 
 
1:51, 200 
 
1:102,400 
 
6 
 
1:6, 400 
 
1:12,800 
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5.3.4.1.1. Th1 immune response 
To determine the Th1 immune response in CBA mice vaccinated with rSjTPI-LD1 and challenged 
with S. japonicum cercariae and infected controls animals (administered only Montanide ISA 
720VG adjuvant), the percentage of CD4
+
 and CD8
+
 splenocytes and liver lymphocytes producing 
IFN-γ at different time points was determined. In addition, the percentage of γδ T cells producing 
IFN-γ was also determined. 
 
At the time just prior to challenge, the percentages of IFN-γ producing CD8+ splenocytes and spleen 
γδ T cells in the vaccinated mice were significantly higher than the infected unvaccinated controls 
when they were re-stimulated with rSjTPI for the former and with rSjTPI and SWAP for the latter 
(Figure 5.7.B and 5.7.E). Moreover, a relatively higher percentage of IFN-γ producing liver CD4+ 
cells from the vaccinated mice was observed compared with the unvaccinated infected and naïve 
controls (Figure 5.7.C). It was not possible to undertake statistical analysis with the liver samples 
as a single pooled liver sample was used per group.  
 
At week 4 post-challenge, a significantly higher percentage of IFN-γ producing CD8+ splenocytes 
was observed in the vaccinated group compared with the infected unvaccinated controls when the 
splenocytes were re-stimulated with rSjTPI (Figure 5.9). However, at week 3, 5 and 6 post-
challenge there was no significant difference in the Th1 immune response generated (Figure 5.8, 
Figure 5.10 and Figure 5.11). 
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Figure 5.7. Frequency of IFN-γ producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at the time point just 
prior to the challenge. Splenocytes and liver lymphocytes were re-stimulated and co-cultured with 
rSjTPI, rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IFN-γ producing CD4+ splenocytes 
from vaccinated, unvaccinated (only adjuvant and PBS administered) and naive CBA mice.  (B) 
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IFN-γ producing CD8+ splenocytes from vaccinated, unvaccinated (only adjuvant and PBS 
administered) and naive CBA mice. (C) IFN-γ producing CD4+ liver lymphocytes from vaccinated, 
unvaccinated (only adjuvant and PBS administered) and naive CBA mice.  (D) IFN-γ producing 
CD8
+
 liver lymphocytes from vaccinated, unvaccinated (only adjuvant and PBS administered) and 
naive CBA mice. For C and D, pooled liver samples taken from five mice per group were used as 
there were insufficient numbers of liver lymphocytes to perform the cell cultures on individual liver 
samples. (E) IFN-γ producing γδ T cells in the spleen. Data are representative of two independent 
experiments. *=p value ≤ 0.05, **=p value ≤0.001. 
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Figure 5.8. Frequency of IFN-γ producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week three post 
challenge. Splenocytes and liver lymphocytes were re-stimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IFN-γ producing CD4+ splenocytes of 
vaccinated and unvaccinated (only adjuvant and PBS administered) CBA mice. (B) IFN-γ 
producing CD4
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice. (C) IFN-γ 
producing CD8
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice. (D) IFN-γ 
producing spleen γδ T cells from vaccinated and unvaccinated CBA mice. For B and C, pooled 
liver samples taken from five mice per group were used as there were insufficient numbers of liver 
lymphocytes to perform the cell culture on individual liver samples.  Data are representative of two 
independent experiments. *=p value ≤ 0.05, **=p value ≤0.001. 
 
 
 
 
 
 
Figure 5.9. Frequency of IFN-γ producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week four post 
challenge. Splenocytes were restimulated and co-cultured with rSjTPI, rSjLD1, SEA, SWAP or 
medium only for 72 hours. (A) IFN-γ producing CD4+ splenocytes from vaccinated and 
unvaccinated (only adjuvant and PBS administered) CBA mice.   (B) IFN-γ producing CD8+ 
splenocytes from vaccinated and unvaccinated CBA mice.  Data are representative of two 
independent experiments. *=p value ≤ 0.05, **=p value ≤0.001. 
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Figure 5.10. Frequency of IFN-γ producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week five post 
challenge. Splenocytes and liver lymphocytes were restimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IFN-γ producing CD4+ splenocytes from 
vaccinated and unvaccinated (only adjuvant and PBS administered) CBA mice. (B) IFN-γ 
producing CD4
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice. (C) IFN-γ 
producing spleen γδ T cells from vaccinated and unvaccinated CBA mice. Data are representative 
of two independent experiments.  
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Figure 5.11. Frequency of IFN-γ producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week six post 
challenge. Splenocytes and liver lymphocytes were re-stimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IFN-γ producing CD4+ splenocytes from 
vaccinated and unvaccinated (only adjuvant and PBS administered) CBA mice. (B) IFN-γ 
producing CD4
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice. (C) IFN-γ 
producing CD8
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice. Data are 
representative of two independent experiments.  
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5.3.4.1.2. Th2 immune response 
Just prior to challenge, a significantly higher percentage of IL-4 producing CD8
+ 
splenocytes 
(markers of a Th2 immune response) was observed in the vaccinated mice when the cells were re-
stimulated with rSjTPI, rSjLD1 and SWAP (Fig 5.12.B). Furthermore, a significantly higher Th2 
immune response by the spleen γδ T cells was evident when they were re-stimulated with rSjTPI, 
SWAP, SEA and even when the cells were cultured only with medium but a similar result was not 
observed when the cells were re-stimulated with rSjLD1 (Figure 5.12.C). 
 
At weeks 3, 4 and 5 post-cercarial challenge, there were no significant differences in the Th2 
immune response among the vaccinated and infected unvaccinated control mice (Figure 5.13, 5.14 
and 5.15). However, at week 6 post challenge, the infected unvaccinated controls induced 
significantly higher Th2 immune response than the vaccinated groups when the splenocytes were 
re-stimulated with rSjTPI (Figure 5.16). 
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Figure 5.12. Frequency of IL-4 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined just prior to 
challenge. Splenocytes and liver lymphocytes were re-stimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IL-4 producing CD4
+
 splenocytes from 
vaccinated, unvaccinated (only adjuvant and PBS administered) and naive CBA mice. (B) IL-4 
producing CD8
+
 spleen lymphocytes from vaccinated, unvaccinated and naive CBA mice.  (C) IL-4 
producing spleen γδ T cells from vaccinated, unvaccinated and naive CBA mice. (D) IL-4 
producing CD8
+
 liver lymphocytes from vaccinated, unvaccinated and naive CBA mice. Data are 
representative of two independent experiments. *=p value ≤ 0.05, **=p value ≤0.001. 
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Figure 5.13. Frequency of IL-4 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week 3 post 
challenge. Splenocytes and liver lymphocytes were restimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IL-4 producing CD4
+
 splenocytes from 
vaccinated and unvaccinated (only adjuvant and PBS administered) CBA mice.  (B) IL-4 producing 
CD4
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice.  (C) IL-4 producing CD8
+
 
liver lymphocytes from vaccinated and unvaccinated CBA mice.  Data are representative of two 
independent experiments.  
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Figure 5.14. Frequency of IL-4 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week four post 
challenge. Splenocytes and liver lymphocytes were re-stimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IL-4 producing CD4
+
 splenocytes from 
vaccinated and unvaccinated (only adjuvant and PBS administered) CBA mice.  (B) IL-4 producing 
CD4
+
 liver lymphocytes from vaccinated and unvaccinated CBA mice. (C) IL-4 producing CD8
+
 
liver lymphocytes from vaccinated and unvaccinated CBA mice. Data are representative of two 
independent experiments.  
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Figure 5.15. Frequency of IL-4 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week five post 
challenge.  Splenocytes and liver lymphocytes were restimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. (A) IL-4 producing CD4
+
splenocytes.   (B) IL-
4 producing CD4
+
 liver lymphocytes. Data are representative of two independent experiments.  
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Figure 5.16. Frequency of IL-4 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week six post 
challenge. Splenocytes and liver lymphocytes were restimulated and co-cultured with rSjTPI, 
rSjLD1, SEA, SWAP or medium only for 72 hours. The IL-4 response was determined at week 6 
post challenge. (A) IL-4 producing CD4
+
 splenocytes of vaccinated, unvaccinated (only adjuvant 
and PBS administered) and naive CBA mice.  (B) IL-4 producing CD8
+
 spleen lymphocytes of 
vaccinated and unvaccinated CBA mice.  (C) IL-4 producing CD4
+  
liver lymphocytes of vaccinated 
and unvaccinated CBA mice.   Data are representative of two independent experiments. *=p value ≤ 
0.05, **=p value ≤0.001. 
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5.3.4.1.3. Th17 immune response 
At week 5 post-challenge, there was no difference in the Th17 immune response among the 
vaccinated and infected controls (Figure 5.17) whereas at week 6 post challenge, the percentage of 
CD4
+
 splenocytes producing IL-17 in the vaccinated mice were significantly higher than the 
unvaccinated but infected controls when re-stimulated with SEA (Figure 5.18.A). A similar result 
was observed in liver γδ T cells when re-stimulated with SWAP (Figure 5.18.C). Moreover, the 
percentage of CD4
+ 
splenocytes, CD4
+ 
liver lymphocytes and liver γδ T cells producing IL-17 was 
relatively higher in the vaccinated group, compared with  the controls when re-stimulated with 
rSjTPI although not significantly (Figure 5.18). 
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Figure 5.17. Frequency of IL-17 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week five post 
challenge. Splenocytes and liver lymphocytes were restimulated and co-cultured rSjTPI, rSjLD1, 
SEA, SWAP or medium only for 72 hours. (A) IL-17 producing CD4
+
 splenocytes from vaccinated 
and unvaccinated (only adjuvant and PBS administered) CBA mice.  (B) IL-17 producing CD4
+
 
liver lymphocytes from vaccinated and unvaccinated CBA mice. (C) IL-17 producing γδ liver T 
cells from vaccinated and unvaccinated CBA mice. (D) IL-17 producing γδ T cells from vaccinated 
and unvaccinated CBA mice. Data are representative of two independent experiments.  
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Figure 5.18. Frequency of IL-17 producing cells from CBA mice that were immunized with 
rSjTPI-LD1 and challenged with S. japonicum cercariae and determined at week six post 
challenge. Splenocytes and liver lymphocytes were re-stimulated and co-cultured with rSjTPI, 
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rSjLD1, SEA, SWAP or medium only for 72 hours. The IL-17 response was determined at week 6 
post challenge. (A) IL-17 producing CD4
+
 splenocytes from vaccinated and unvaccinated (only 
adjuvant and PBS administered) CBA mice.  (B) IL-17 producing CD4
+
 liver lymphocytes from 
vaccinated and unvaccinated CBA mice. (C) IL-17 producing liver γδ T cells. (D-E) Representative 
staining showing γδ TCR+ IL-17+ liver lymphocytes. (D) Gamma delta TCR+  IL-17+  liver 
lymphocytes in CBA mice vaccinated with rSjTPI-LD1 and re-stimulated with rSjTPI  (E) Gamma 
delta TCR
+  
IL-17
+ 
 liver lymphocytes in CBA mice administered only with Montanide ISA 720 VG 
(Adjuvant). Data are representative of two independent experiments. *=p value ≤ 0.05, **=p value 
≤0.001. 
 
 
5.3.4.2. T regulatory immune response in CBA mice vaccinated with rSjTPI-LD1 and 
challenged with S. japonicum cercariae compared with unvaccinated infected controls 
In order to assess the effects of rSjTPI-LD1 on the T regulatory immune response in CBA mice, the, 
frequency of Tregs at different time points (week 0,3,4,5 and 6) post challenge was determined. At 
all of the time points post challenge, the vaccinated mice demonstrated a higher percentage of Tregs 
than the infected controls when the splenocytes were re-stimulated with rSjLD1 (Figure 5.19). Just 
prior to challenge, splenocytes from the vaccinated mice cultured with medium only (i.e. without 
re-stimulation with antigen) showed a significantly higher percentage of Tregs than naïve controls 
(Figure 5.19.A). At week 4 post challenge, the infected unvaccinated control mice demonstrated a 
higher Treg response than the vaccinated mice when the splenocytes were re-stimulated with SEA 
and SWAP (Figure 5.19.C). 
 
For all time points except week 6 post challenge, liver samples were pooled per group as the 
number of liver lymphocytes obtainable were insufficient to culture from individual mice; a 
relatively higher Treg response was observed among the vaccinated groups compared with 
unvaccinated infected controls when re-stimulated with rSjLD1(Figure 5.20). 
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Figure 5.19. Frequency of spleen Tregs from CBA mice that were immunized with rSjTPI-
LD1 and challenged with S. japonicum cercariae. The Tregs percentage was determined at 
different time points post challenge. Single cell suspensions of the splenocytes were co-cultured 
with rSjTPI, rSjLD1, SEA, SWAP or medium only for 72 hours. (A) Just prior to challenge. (B) At 
week 3 post challenge.  (C) At week 4 post challenge.  (D) At week 5 post challenge.  (E) At week 
6 post challenge. (F) Flow cytometry chart showing Tregs (CD4
+
 CD25
+
FoxP3
+
) in splenocytes of 
naïve, adjuvant administered and vaccinated (with rSjTPI-LD1) mice and re-stimulated with the 
rSjLD1 protein. Data are representative of two independent experiments. *=p value ≤ 0.05, **=p 
value ≤0.001. 
 
 
Figure 5.20. Frequency of liver Tregs from CBA mice that were immunized with rSjTPI-LD1 
and challenged with S. japonicum cercariae. Single cell suspensions of liver lymphocytes were 
co-cultured with rSjTPI, rSjLD1, SEA, SWAP or medium only for 72 hours. (A). Just prior to 
challenge. (B) At week 3 post challenge. (C) At week 5 post challenge. (D) At week 6 post 
challenge. Data are representative of two independent experiments.  
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5.4. Discussion 
 
Vaccine development is one of the key elements of the integrated approach for schistosomiasis 
control and elimination [297]. There are a number of schistosomiasis vaccine candidates that are at 
different stages of development and trialing, with many of these molecules resulting in reduced 
worm and egg numbers in vaccinated mammalian hosts. At QIMRB, this laboratory has focused for 
several years on two vaccine candidates, the recombinant ligand binding domain of insulin receptor 
(rSjLD1) and triose phosphate isomerase (rSjTPI). In this thesis chapter, an antigen mix comprising 
the two recombinant proteins (rSjTPI-LD1) was assessed for protective efficacy against S. 
japonicum in vaccine/challenge trials using the murine model of schistosomiasis. As earlier 
described in Chapter 4, there is need to determine the specific effect of any vaccine candidate on the 
immune response against schistosomiasis when mice are used as the model system. Here, the 
protective efficacy of rSjTPI-LD1 was determined by estimating the percentage of worm and liver 
egg reduction in vaccinated/cercarial challenged mice compared with unvaccinated but infected 
controls. CBA mice were immunized three times (primary vaccination with two boosts) at two 
week intervals with rSjTPI-LD1 formulated with Montanide ISA720VG adjuvant, and challenged 
with S. japonicum cercariae two weeks after the second vaccine boost. An adjuvant control group 
was injected with PBS and the adjuvant only, and naïve mice (not vaccinated, not challenged), 
served as an additional control group. 
 
Two independent vaccine trials were conducted and in both, there were statistically significant 
reductions in the number of adult worms and paired worms (Figure 5.2), and in the number of eggs 
in the mouse liver egg reduction (Figure 5.3). In regards to the reduction in worm numbers, the 
protection obtained (22.3% - 26%) was comparatively lower than some, but not all schistosome 
vaccine candidates (Chapter 1, Table 2), and our findings are similar to the protective efficacy 
obtained with other schistosome vaccine candidates that have been tested [297, 298]. This low level 
of worm reduction might be due to the fact that the rSjTPI-LD1 vaccine may target parasite growth 
and development rather than actual killing of the S. japonicum worms. This outcome is similar to a 
study conducted on the vaccine efficacy of rSjLD1 on its own, wherein, no significant worm 
reduction was observed [230]. However, the rSjTPI-LD1 vaccine resulted in significant liver egg 
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reduction (41%-54% (Figure 5.3)), similar to the efficacy of a number of other schistosome vaccine 
candidate (Table 2; Chapter 1). However, the liver egg reduction observed in this study was higher 
than some other schistosome vaccine candidates [230, 298]. The considerable liver egg reduction 
likely reflects the ability of the rSjTPI-LD1 vaccine candidate to reduce pathology and transmission 
of S. japonicum through reduced egg output.  
 
Following the preparation of single cell suspensions from mouse spleens and livers, the numbers of 
splenocytes and liver lymphocytes were estimated at different time points in the challenged mice. In 
the spleen, there was no significant difference in the number of the cells between the vaccinated and 
infected controls but in both groups the number of splenocytes increased from the time of challenge 
up to week 3 post challenge. However, the numbers declined after week 3 up to week 5 post 
challenge (Figure 5.5). The increase in the number of splenocytes  may be due to  the murine host 
developing an immune response against the adult schistosome worms as it is well documented that 
it takes about 3 weeks for S. japonicum to grow and develop and become fully mature [299]. 
However, the number of liver lymphocytes increased over the course of infection. The difference in 
the trend in the number of spleen and liver lymphocytes over the course of infection maybe due to 
immune response shifts at some time point (probably at week 4 post-challenge) from a systemic 
spleen response to a more localised liver response as this is the location where the schistosome eggs 
accumulate.  
 
Immunization of mice with the adjuvanted rSjTPI-LD1 vaccine induced a humoral response 
evidenced by the production of significantly high levels of anti-rSjTPI and anti-rSjLD1 IgG 
antibodies (Figure 5.6). Sera were prepared from CBA mice at the time point just prior to challenge 
and at weeks 3, 4, 5 and 6 post challenge and the levels of anti rSjTPI and rSjLD1 IgG antibodies 
were measured using ELISA. The level of specifc IgG peaked at week 4 post challenge for both 
rSjTPI and rSjLD1 may be related to the number of splenocytes produced (peaking at week 3 post 
challenge). With other schistosome vaccines (e.g. Sm-p80)  IgG level peaks later than week 4 [300]. 
The levels of anti- rSjTPI and anti-rSjLD1 IgG antibodies started to decline at week 5 post 
challenge which may represent the time point where there was a progressive decline in memory T 
cells to the parasite [301].  
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In order to examine T cell mediated immunity in the CBA mice vaccinated with rSjTPI-LD1 and 
challenged with 34 cercariae of S. japonicum, spleens and livers were collected at different time 
points. At the time of just prior to challenge, rSjTPI-LD1 induced a significant Th1 immune 
response mediated by spleen CD8
+
 T cells (re-stimulated with rSjTPI) and γδ T cells (re-stimulated 
with rSjTPI and SWAP) (i.e. a significantly higher percentage of IFN-γ producing CD8+ and γδ T 
cells) in the vaccinated mice compared with the unvaccinated infected control animals. Gamma 
delta T cells are known to induce an early Th1 immune response against both extra cellular and 
intracellular pathogens, co-related with macrophage recruitment [302-305]. The Th1-mediated 
immune response by the γδ T cells with macrophage activation may have contributed to the 
protection induced by rSjTPI-LD1. However, further study on the characterization of the stimulated 
γδ T cells will be crucial. Moreover, the Th1 immune response mediated by spleen CD8+ cells at the 
time of challenge may be due to the fact that γδ T cells play a role in the induction of  the CD8+ T 
cell response [306]. On the other hand, a Th1 immune response mediated by CD4
+
 was not 
observed in the vaccinated group which may be due to suppression of CD4
+
 cells by γδ T cells [307, 
308]. Gamma delta T cells play a role in humoral immunity by helping the production of antibodies 
through induction of T follicular helper cell differentiation indicating the high IgG response to both 
rSjTPI and rSjLD1 in this study might be due in part to the γδ T cell response [309]. 
 
Furthermore, at week 4 post challenge, there was significantly higher percentage of CD8
+ 
splenocytes producing IFN-γ in the vaccinated mice than the unvaccinated but infected control 
animals when the cells were re-stimulated with rSjTPI. This also supports the concept that rSjTPI-
LD1 consistently induces a Th1 immune response at the early phase of infection which might 
contribute to the worm and liver egg reduction demonstrated in this study. Moreover, rSjTPI seems 
to be a better inducer of the Th1 immune response than rSjLD1. 
 
Just prior to challenge, a higher percentage of IL-4 producing spleen CD8
+
 T cells (i.e. a Th2 
immune response) was shown in the vaccinated mice compared with the control group when the 
cells were re-stimulated with rSjTPI, rSjLD1 and SWAP. A similar result was obtained with the 
liver CD8
+
 T cells when re-stimulated with rSjTPI and rSjLD1 (statistical analysis for the liver 
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samples was not undertaken as a single pooled sample was used for each group due to the small 
number of cells available). The vaccinated group also demonstrated a significantly higher 
percentage of IL-4 producing gamma delta T cells when the cells were re-stimulated with rSjTPI, 
SEA, SWAP and even without any re-stimulation. It has been reported that IL-4/IL-4R interaction 
on CD8
+
 cells promotes the development of memory cells in parasite immunization [310]. In 
addition, for some parasites such as Leishmania, IL-4 is essential for the induction of CD8
+
 T cell 
mediated vaccine induced protective immunity [311]. However, at other time points (weeks 3, 4, 5) 
there were no significant differences in the induced Th2 immune response between the rSjTPI-LD1 
vaccinated and control groups and this could be due to suppression of the T effector immune 
response by γδ T cells, a T regulatory immune response or some other mechanisms.  
 
At week 6 post challenge (time point when most liver eggs were present) (Chapter 2, Figure  
2.5.C), there was a higher percentage of IL-4 producing spleen CD4
+
 T cells among the 
unvaccinated but infected group compared to the vaccinated mice when re-stimulated with rSjTPI 
(Figure 5.16.A). This might be due to the fact that Th2 immune response targets schistosome eggs 
rather than adult parasites, as discussed in Chapter 1, and the unvaccinated but infected mice 
harbour more liver eggs compared to the vaccinated mice (Figure 5.3) which as a result might 
contribute to the induction of more vigorous Th2 immune response. 
 
In regards to the Th17 immune response, the vaccinated mice demonstrated a higher percentage of 
spleen CD4
+
 T cells and liver γδ T cells producing IL-17 when they were re-stimulated with SEA 
and SWAP, respectively. Re-stimulation with rSjTPI or rSjLD1 did not induce significantly 
different IL-17 responses among the groups which suggests that a combination of more than a 
single schistosome protein may be required to trigger a significant IL-17 response as SWAP and 
SEA are cocktails of many schistosome proteins. 
 
In addition to T effector immune responses (Th1, Th2,Th17), the Treg immune response was 
evaluated after CBA mice were vaccinated with rSjTPI-LD1 and challenged with S. japonicum 
cercariae. At all of the time points (just prior to challenge and week 3, 4, 5 and 6 post challenge), 
the vaccinated mice had a significantly higher percentage of Tregs in the spleen when re-stimulated 
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with rSjLD1 (Figure 5.19), clearly showing that rSjLD1 is a Treg stimulator. Similar to these 
findings, other schistosome vaccine candidates such as SjHSP60 derived peptide (SjMHE1) and 
pVAX1-Sj26GST also induced a significantly high percentage of Tregs [312, 313].  Although Tregs 
are very important in regulating an increased immune response following vaccination, it should also 
be noted that the Treg response may reduce vaccine-induced immunity [314-317]. Tregs also 
suppress T effector cells by consuming IL-2 through the α CD25 subunit of the IL-2 receptor as IL-
2 is essential for growth and survival of T effector cells and eventually induces apoptosis [64]. 
Therefore, the low protective efficacy, in terms of reduced worm numbers (22.3%-26%), generated 
may be due to the suppression of the effector immune response by Tregs. As Tregs may reduce the 
immune response induced by vaccination, it may be that redesigning the rSjTPI-LD1 vaccine in a 
way that depletes Treg may improve its protective efficacy. There are different methods available to 
deplete Tregs such as using an alternative adjuvant such as Cimetidine, and/or administering the 
vaccine candidate with anti-CD25 monoclonal antibodies [314, 318-323], using transgenic mice 
where FoxP3
+
 is deleted [324], or by other approaches [325]. Therefore, depletion of Tregs can 
potentially improve the protective efficacy of vaccine candidate. However, one study on murine 
schistosomiasis showed that depletion of Tregs before administering a DNA vaccine encoding a 26 
kDa glutathione S-transferase of S. japonicum (pVAX1-Sj26GST) did not confer improved 
protection even though it increased the proliferation of splenocytes and IgG levels [313]. Clearly, 
different vaccine molecules and the way they are formulated and presented may impact on the 
generation of immune protection with or without CD25
+
 (Treg) cell depletion. 
  
Overall, this study showed the vaccine candidate, rSjTPI-LD1, adjuvanted with Montanide ISA 
720VG, was able to confer in mice a marginal reduction in S. japonicum worm numbers but, more 
encouragingly, a relatively high reduction in liver eggs. A Th1 mediated immune response governed 
by γδ T cells was induced by the vaccine before challenge infection. Furthermore, a Th2 immune 
response by CD8
+
 splenocytes was observed before challenge and at the early phase of infection 
(week 4 post challenge). However, rSjLD1 significantly stimulated the generation of Tregs which 
may have dampened the protective immune response, resulting in the low level of worm reduction 
in the vaccinated mice. These latter findings have implications for further studies aimed at 
determining whether the depletion of Tregs prior to vaccine administration can boost the protective 
immune response resulting in improved vaccine efficacy. 
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                                               Chapter  6 
                          General Discussion and Future Directions 
 
6.1. General discussion 
 
Schistosomiasis control is one of the targets of WHO as it considers its role in the integrated 
elimination of the neglected tropical diseases [220]. Using praziquantel (PZQ) as the sole anti-
schistosomiasis intervention is not effective and the development of PZQ-drug resistance is a 
constant threat [24-29]. Anti-schistosome vaccine development and deployment is considered one 
of the options for integrated schistosomiasis control and elimination. Indeed, a number of current 
vaccine candidates are under different stages of development with some showing promising signs 
although an effective commercial vaccine is still not available. Among the available vaccine 
candidates, an antigen mix (rSjTPI-LD1) against schistosomiasis japonica is under proof of concept 
in mice [34] (Chapter 1). 
 
The fact that schistosome parasites have several life cycle stages, each expressing different 
antigens, and that schistosomes are diploid pathogens presents a double advantage to these parasites 
in evading the immune response or making the immune response against them very complex [41, 
326]. It is obvious that any candidate vaccine should boost any existing native immune response 
which makes a solid understanding of immune mechanisms essential. It is important to study the 
immune response against each parasite species and strain and in diverse mammalian hosts including 
different mouse strains. Knowledge of the type of protective immunity that is boosted by any 
vaccine candidate and understanding the limitations of any vaccine candidate in generating  
effective protective immunity are essential elements in the path to developing an effective anti-
schistosome vaccine. 
 
The research presented in this thesis demonstrated that there is a Th1-Th2 shift at the time when 
adult female worms of S. japonicum commence egg laying, a feature similar to that found in S. 
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mansoni [19]. At the early phase of S. japonicum infection, the predominant T effector immune 
response was shown to be Th1-mediated. Moreover, one of the main findings of this study 
(Chapter 2) was the consistent increase in Treg response over the time course of infection before 
the schistosome parasite commenced egg laying. Therefore, the Th1 immune response exhibited a 
similar pattern to that of the Treg immune response both of which were relatively high before the 
commencement of egg laying. The study also showed that the majority of challenging cercariae 
(more than 70%) successfully matured to adult parasites, as determined at perfusion, indicating the 
Th1 immune response was not sufficiently effective to kill parasites probably being suppressed by 
the Treg immune response; we thus speculate the parasite may induce a Treg [327] response as an 
escape mechanism thereby avoiding immune killing [250, 255, 327-331]. Moreover, in rSjTPI-LD1 
vaccinated and S. japonicum cercariae challenged mice (Chapter 5), there was a generation of a 
high percentage of Tregs when cells from the mice were co-cultured with rSjLD1 suggesting that 
this protein can also induce Tregs. Therefore, the generation of Tregs induced by the parasite itself 
(Chapter 2) and a component of the rSjTPI-LD1 vaccine (Chapters 4 and 5) may suppress the 
protective Th1 immune response. 
 
It was not only the T cell immune response but also the humoral immune response in a natural S. 
japonicum infection which seemed predominantly directed against the parasite egg stage rather than 
the adult parasite; it was clearly shown that significant amounts of IgG antibodies were generated 
against the egg-derived (SEA) antigen with the peak response shown at week 6 post challenge 
(Chapter 2). 
 
Even though the immune response at the early phase of infection is predominated by Th1, we 
demonstrated that the level of the response is very low compared to the Th2 immune response at the 
later phase of infection. Therefore, it might in future be advantageous to manipulate the immune 
response by boosting the Th1 immune response at an early phase of infection before the female 
schistosome commences egg laying.  
 
Our laboratory has targeted the ligand binding domain (LD1) of insulin receptors (SjIRs) and triose-
phosphate isomerase (rSjTPI) as putative vaccine candidates against Schistosomiasis japonica both 
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showing encouraging levels of immunological protection in mice. Accordingly, we designed an 
antigen mix combining these two recombinant proteins and tested their immunogenicity and 
protective efficacy in CBA mice. 
 
It is crucial to confirm whether any vaccine candidate is capable of inducing a protective immune 
response. Therefore, we administered rSjTPI-LD1 with Montanide ISA 720VG into CBA mice and 
evaluated the immune response generated (Chapter 4). As a result, significantly high anti-rSjTPI 
and anti-rSjLD1 IgG antibodies were generated up to week 8 post the last booster vaccination with 
the peak antibody levels observed at week 6 post the last boost. We demonstrated a significantly 
higher percentage of IFN-γ producing spleen γδ T cells and CD8+ T cells in the rSjTPI-LD1 
vaccinated mice compared with unvaccinated mice at week 2 post the last booster vaccination. 
However, there was no difference among the mouse groups in the induction of both the Th1 and 
Th2 immune response by CD4
+
 cells. Generally, a significant T cell immune response was observed 
at the time point just prior to cercarial challenge (i.e. at week 2 post last booster vaccination). 
However, in Chapter 5 involving cercarial challenge following vaccination, the vaccinated group 
demonstrated a significant involvement of CD8
+
 cells in a Th1 immune response at week 4 post 
challenge. This may be due to the fact that in the vaccinated and challenged mice there was 
relatively frequent exposure to schistosome antigen, resulting in the generation of memory cells. 
 
The study demonstrated a sufficient level of protection (i.e., low worm burden reduction but 
relatively high liver egg reduction) that encouraged us to evaluate the immune response associated 
with the generated protection against S. japonicum. Similar protocols to those undertaken in 
Chapter 4 were employed to evaluate the immune response generated. 
 
Just prior to challenge, rSjTPI-LD1 induced both Th1 and Th2 immune responses mediated by γδ T 
and CD8
+
 T cells implying that before induction of the immune response by the parasite a mixed 
Th1/Th2 immune response was generated by the vaccine. rSjTPI-LD1 also induced a significant 
Th1 immune response (IFN-γ producing CD8+ T cells) at the early phase of infection (week 4 post 
challenge) and the reduction in worm and liver egg numbers could be partially related to this 
immune response. The Th1 immune response was also the predominant immune response at the 
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early phase of the natural infection (Chapter 2), a response that might be strengthened by 
vaccination with rSjTPI-LD1 and help clear the schistosome parasites.  However, the CD4
+
 T cells 
did not show any difference in the immune response the vaccine generated among the vaccinated 
compared with the infected controls which could be due to the response being suppressed by Tregs 
and the γδ T cell response. 
 
A significant humoral immune response was also induced which was demonstrated by production 
of anti-rSjTPI and anti-rSjLD1 IgG antibodies at all time points post cercarial challenge with the 
highest peak in the level of antibodies shown at week 4 post challenge. The antibody response could 
also have contributed to the protection induced by the vaccine. 
 
In this thesis, it was also demonstrated that there was significant vaccine-induced Treg immune 
response. It has been reported in a number of studies that a vaccine-induced Treg response 
considerably limits the protective potential of the vaccine. We demonstrated that the induction of 
Tregs was particularly evident following the re-stimulation of cells from the rSjTPI-LD1-vaccinated 
mice with rSjLD1 protein. Therefore, this induction of Tregs in the vaccinated mice may contribute 
to the suppression of the protective Th1 immune response. Involvement of γδ T cells in vaccine-
induced immunity has not, hitherto, been studied in schistosomes, based on a review of the 
literature.. Therefore, this study is likely to be the first of its kind in revealing the possible 
involvement of γδ T cells in immunity against schistosomiasis. Further studies in characterization of 
the γδ T cells may reveal which subtype is involved. 
 
The rSjTPI-LD1 vaccine induced a significant Th17 immune response at week 6 post challenge. 
Vaccine induced IL-17 mediated immunity has been clearly shown to be one of the hallmarks of 
vaccine-induced memory responses [332, 333]. The percentage of spleen CD4
+
 and liver γδ T cells 
producing IL-17 in the vaccinated mice was significantly higher than in the unvaccinated but 
infected controls, similar to a previous report with a helminth infection [334]. The IL-17 mediated 
immune response has also been reported to be protective in other parasites [334, 335]. 
Administrating recombinant IL-17 protein with the rSjTPI-LD1 may improve the protective 
efficacy but one cautionary report indicated a relationship between high IL-17 involvement and 
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schistosomiasis pathology [68]. Therefore, it is important that further studies be carried out to 
determine the degree of IL-17-induced pathology as well as the protective potential of this cytokine 
when administered concurrently with the rSjTPI-LD1vaccine. 
  
The main aims of this study were to explore the immune response against schistosomiasis japonica 
and to examine the effects of the rSjTPI-LD1 candidate vaccine on the T cell immune response 
against S. japonicum infection. These aims were addressed by revealing the features of the 
Th1/Th2/Th17 and Treg immune responses during infection and vaccination. The possible 
immunological reasons why the rSjTPI-LD1 vaccine resulted in only a moderate level of worm 
killing remain to be fully elucidated so that, further studies on how the vaccine may modulate the 
immune response can promote more effective vaccine design and improve on  vaccine efficacy. 
 
6.2. Future Directions 
 
Based on the extensive literature review (Chapter 1) of different vaccine candidates for 
schistosomiasis, protective immunity, whether due to a Th1 and/or Th2 response, appears mainly to 
be governed by CD4
+ 
T cells or CD8
+
 T cells. The involvement of γδ T cells during schistosome 
infection, particularly an IL-17 mediated immune response, has been reported for S. japonicum. 
Moreover, studies on other pathogens such as M. bovis [336], Plasmodium species [337] and 
Listeria monocytogens [338] clearly demonstrated the involvement of γδ T cells in immunity. 
However, studies on vaccine-induced γδ T cells during schistosome infection have not previously 
been reported, so the findings in this thesis regarding vaccine induced γδ T cells, particularly 
relation to the in Th1 immune response provide a starting point for further studies.  As γδ T cells are 
diverse [339], which subsets are involved in the protective immune response against 
schistosomiasis needs further elaboration. Characterization of the γδ T cells and identifying the 
subsets that are typically involved in protective immunity against schistosomes can contribute to 
improved vaccine design. 
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This study demonstrated that rSjLD1 induced a significant high Treg immune response. A Treg 
immune response is useful as it modulates or limits tissue damage that can occur due to the pro-
inflammatory immune response generated by a vaccine candidate. On the other hand, the Treg 
immune response may suppress the protective immunity. In this study, one of the reasons why the 
rSjTPI-LD1 vaccine induced a lower level of anti-worm protective immunity compared with a 
number of other schistosome vaccine candidates (Tables 1.1 and 1.2, Chapter 1), might be due to 
the fact that rSjLD1 induced a sufficiently large Treg response that suppressed the T effector 
immune response. Consequently, further studies designed to deplete Tregs numbers could improve 
the level of protection generated by the rSjTPI-LD1 vaccine. 
  
This thesis examined the immune response against S. japonicum in the less studied CBA mouse 
strain. The work showed that the well-recognized Th1-Th2 shift evident in S. mansoni infection also 
occurs in S. japonicum. It was also shown that the increased involvement of a Treg immune 
response at the early phase of a S. japonicum infection compared with the later stage might reflect 
the induction of Tregs by the parasite to evade the immune response before the onset of egg laying. 
The thesis also demonstrated the involvement of γδ T cells in IL-17 mediated immunity and showed 
the highest percentage of IL-17 producing liver γδ T cells compared to CD4+ T cells and CD8+ T 
cells. Moreover, at the early phase of infection the Th1 immune response was highest against the 
adult worm antigen (SWAP) than the egg-derived antigen (SEA) whereas at the later phase of the 
immune response (after the commencement of egg laying) the dominant Th2 immune response 
targeted SEA. 
 
The multivalent rSjTPI-LD1 vaccine was designed and developed in this thesis and in vaccine trials 
I resulted in significant reductions in worm and liver egg burdens indicating its promise as a 
potential intervention tool to prevent transmission of zoonotic schistosomiasis. The rSjTPI-LD1 
vaccine induced Th1 and Th2 immune responses just prior to challenge with S. japonicum cercariae 
whereas a Th1 and Th17 immune response was evident after challenge. Moreover, one of the 
vaccine protein components, rSjLD1, was shown to be a high Treg stimulator. Taken together, the 
work described in this thesis demonstrated that the rSjTPI-LD1 vaccine had a positive effect on the 
T cell immune response (predominantly a Th1 immune response). Additionally, it demonstrated the 
significant involvement of γδ T cells in vaccine-induced immunity. In summary, this thesis provides 
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information on the immune response against schistosomiasis japonica in CBA mice and on the 
effects of the rSjTPI-LD1vaccine on the T cell immune response against S. japonicum. Taken 
together, these novel outcomes points the way forward for improving the protective efficacy of 
rSjTPI-LD1 and other candidate vaccines against schistosomiasis through modulation of the T cell 
immune response. 
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